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According to the Canadian Institute of Health Research and the Institute of 
Musculoskeletal Health and Arthritis, more than 400 million people around the world 
suffer from crippling, chronic pain of joint disease, osteoporosis, spine diseases and 
musculoskeletal trauma, and this number is predicted to increase to 570 million 
people by the year 2020 (1).  Epidemiological studies and studies with animal models 
have associated the deficiency of iodine (I) and selenium (Se) with a type of 
osteoarthritis (OA) occurring in children in the first or second decade of life (2-5).  
Even though an inverse relationship between osteoarthritis and bone density or 
osteoporosis has been documented (6-8), local bone loss near affected joints and 
reduced BMD in non-articular bones is well recognized in both OA and rheumatoid 
arthritis (RA) (8-11).   
Arthritis consists of conditions that affect the joints and surrounding tissues.  
The most common forms of arthritis are OA and RA (12).  Approximately 40 million 
Americans are suffering from arthritis, and this number will increase to 59.4 million 
by the year 2020 (13).  The Centers for Disease Control in its morbidity and mortality 
weekly report (14) noted 21% of US adults suffer from arthritis with blacks having 
similar prevalence to that of white people.  Arthritis does not affect only the elderly, 
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even though the risk increases with age.  Approximately 300,000 children in the 
United States suffer from some form of arthritis or rheumatic diseases.  There are 8.4 
million young adults between the ages of 18-44 who have arthritis and millions of 
others are reported to be at risk for developing it (15).   
Osteoporosis is a metabolic bone disease characterized by low bone mineral 
density and microarchitectural deterioration of bone leading to its fragility and 
subsequent fracture (16).  Each year in the United State, osteoporosis leads to a million 
and half fractures, mostly of the hip, spine and the wrist (17), and 12 - 20% of patients 
with hip fracture die within a year after fracture, usually from complications such as 
pneumonia, and blood clots in the lung, which are related to the fracture or the surgery to 
repair the fracture (12).  The estimated national direct expenditures (hospitals and nursing 
homes) for treatment of osteoporosis and associated fractures was $17 billion in 2001 
($47 million each day) and the cost is rising (17).  
While we experience this alarming situation, several factors have been implicated 
in the etiology of bone and articular diseases.  Iodine and selenium deficiencies have 
been associated with osteoarthritis (2-3, 18) and osteoarthritis leads to bone loss (9, 11, 
19).  Unfortunately, iodine and selenium deficiencies are still major public health 
problems in many parts of the developing world. 
 The best known role of iodine in mammalian systems is for the synthesis of 
thyroid hormones which regulate multiple physiological processes including bone 
development, growth, and maintenance (20).  Despite great strides made in human 
nutrition in the previous decades, deficiencies of iodine and selenium still exist in many 
countries.  The World Health Organization estimates that 740 million people suffer from 
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iodine deficiency disorders (IDD) globally comprising 13% of the world population.  An 
additional 30% are classified as at risk (21).  Iodized salt has alleviated IDD in many 
parts of the world, but it is estimated that in countries with IDD, 1.6 billion people still do 
not have access to iodized salt (21).   
Selenium is an essential trace element for humans.  Its appearance in the food 
supply is closely related to geologic factors affecting soil selenium (22).  Deficiency 
symptoms for selenium are linked to its normal uses in the body.  It is an essential 
cofactor for glutathione peroxidases, enzymes that protect tissues from oxidative damage 
(23).  Another vital role of selenium is in the conversion of the thyroid hormone 
thyroxine (T4) to triiodothyronine (T3), as a component of the selenoprotein 
5’iodothyronine deiodinase, the enzyme responsible for this conversion (24).  During 
selenium-deficient conditions, iodine can be held in the T4 fraction by selenium 
deficiency’s effects (25).   
Selenium adequacy is required for normal thyroid function (24).  In addition to 
the activation and the homeostasis of thyroid hormones, selenium may protect thyroid 
cells against oxidative damage, and thus improve thyroid function (25).  Kashin-Beck 
disease (Osteoarthritis deformans endemica) is an endemic osteoarthropathy that affects 
the bone and joints of its sufferers, with a typical onset in the first or second decade of 
life (26).  Selenium and iodine deficiencies have been associated with the disease (2, 5). 
The mechanism whereby iodine and selenium may affect bones and joints is not 
clear.  However, thyroid hormone (T3) is believed to have an important role in the 
development and maintenance of both endochondral and intramembranous bone (27).  
Selenium is required for thyroid hormone metabolism.  In addition, selenium may protect 
4
bone and cartilage cells against oxidative damage (28).  Despite the studies showing 
effects of iodine and selenium on bone, there is limited information on the effects of these 
trace elements on characteristics of bone such as density, microarchitecture, and strength 
during growth.  There is also insufficient data on gender difference in bone response to 




The objectives of this study were  
1. To investigate the effects of iodine and/or selenium depletion on growth and bone 
quality of growing male and female rats by assessing indicators of growth, bone 
density, microarchitecture, strength, and selected  biochemical markers of bone 
metabolism.  
 





To accomplish the above-cited objectives the following null hypotheses were proposed:  
H01: Iodine and/or selenium depletion will not significantly reduce growth and bone 
density of growing rats. 
H02: Iodine and/or selenium depletion will not negatively affect biochemical markers of 
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bone metabolism and oxidative status of growing rats. 
H03: Iodine and/or selenium depletion will not significantly deteriorate the  
 microarchitecture of growing rat bone. 
H04: Iodine and/or selenium depletion will not impair biomechanical properties of the   
 bone of growing rats  





Iodine and selenium deficiencies have been associated with retarded growth, 
osteopenia and osteoarthritis in growing individuals (2-3).  Since osteoarthritis has 
been shown to cause bone loss, it is possible that iodine and selenium deficiency-
related osteoarthritis may lead to increased bone fracture risk in the affected growing 
individuals.   
Treatment options for both arthritis and osteoporosis are not without limitations 
and serious adverse side effects, and alternative ways of prevention and treatment are 
being investigated.  If this study is confirmed by more animal and controlled clinical 
human studies, it may serve as a basis for dietary recommendation for preventing or 




Organization of the Dissertation 
 
There are different ways of approaching investigation of effects of iodine and 
selenium depletion on bone using an animal model.  This dissertation reviews key 
literature on functions, food sources and requirements for iodine and selenium, as well as 
bone disorders such as osteoporosis and arthritis and their relation with iodine and 
selenium deficiency.  Following the review of the literature and methodology section, is a 
chapter prepared as a journal article for submission to the Journal of Nutriton.  In the 
study presented in the form of journal article, lactating dams were fed iodine and/or 
selenium depleted diets and growth, iodine and selenium status, bone strength and 
structure, biochemical markers of bone metabolism, and antioxidant status were assessed.  
These chapters are followed by a chapter containing summary and conclusions, as well as 
suggestions for future study.  Means for the differents dietary groups are presented in 
Appendices D through Q. Tables associated with chapter IV present  factor means.  The 





REVIEW OF THE LITERATURE 
 
Physiological Functions of Iodine and Selenium  
 
Physiological Functions of Iodine
The best-known role of iodine in mammals is its use in the synthesis of the 
thyroid hormones, thyroxine (T4) and triiodothyronine (T3) (29).  Thyroid hormones 
regulate a variety of physiological processes such as growth and development of many 
organs including the skeleton (30) metabolism rate, protein synthesis, and 
thermoregulation (31).  Thyroid hormone (T3) directly stimulates its cell nuclear 
receptors influencing expression of several genes including those that regulate bone 
growth and function (30).   
An insufficient dietary supply of iodine results in a variety of disorders grouped 
under the general heading of iodine deficiency disorders (IDD).  Among these are goiter, 
abortion, stillbirth, decreased cognitive function, increased infant mortality, cretinism 
(31), cardiac insufficiency and iodine-induced hyperthyroidism (32).  Iodine deficiency 
may also contribute to Kashin-Beck disease (33), a severe type of osteoarthritis reported 
in children and adolescents in certain areas of China and Tibet (2).
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Physiological Functions of Selenium
Selenium is an essential trace element for humans.  It acts in the body in the form 
of different selenoproteins, eighteen of which have been identified (23).  These 
selenoproteins include four different glutathione peroxidases (GSH-Px 1, 2, 3 and 4), 
which catalyze the reduction of peroxides that can cause cellular damage (23-24, 34), and 
three iodothyronine deiodinases (types I, II and III) that are required for thyroid hormone 
metabolism and homeostasis (24, 35).  Other selenoproteins mentioned by Sunde (23) 
and the Food and Nutrition Board (35) include three thioredoxin reductases (1 through 3) 
involved in the reduction of intramolecular disulfide bonds and the regeneration of 
ascorbic acid from its oxidized metabolites, selenoprotein P which is also involved in 
oxidant defense, selenoprotein W involved in muscle metabolism, and  selenophosphate 
synthetase having a role in cancer protection (23) and required for selenium metabolism 
(35).   
In addition to the activation and homeostasis of thyroid hormone, selenium as part 
of key antioxidant enzymes may improve thyroid function by protecting its cells against 
oxidative damage.  Iodine deficiency results in the hyperstimulation of the thyroid by 
thyroid stimulating hormone (TSH) and consequently in increased production of 
hydrogen peroxide (H2O2) within the thyroid cells.  Selenium adequacy may prevent the 
accumulation of H2O2 and thus thyroid cell destruction and thyroid failure (25).  It is 
believed that selenium may protect bone and cartilage cells against oxidative damage in a 
similar manner (23). 
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Food Sources of Iodine and Selenium  
 
The use of iodized salt has been the most effective means for control of iodine 
deficiency.  Sea fish and other marine foods are frequently regarded as the most 
important natural sources of dietary iodine.  Even in inland areas, fish remains the highest 
natural iodine food source (36).  Milk and crops from iodine sufficient geographical areas 
may also be good sources of iodine.   
The appearance of selenium in the food supply is related to the selenium content 
of the soil where the foods are grown (22).  In regions with low selenium soil, 
deficiencies arise if the diet is confined to foodstuffs grown in that region. 
Selenium is associated with protein in animal tissues.  Selenium deficiency can be 
worsened by protein energy malnutrition (PEM).  PEM has a dual impact on selenium 
status because selenium is often bound to the amino acid methionine in the consumed 
protein.  In addition, low methionine intake forces the body to use seleno-methionine 
complexes in the manufacture of body proteins making the selenium unavailable until the 
protein is degraded by the body (23).  Consequently meats (muscle meats and organ 
meats), and seafood are dependable dietary sources of the mineral (34).  However, the 
selenium contents of grains and seeds vary depending on the content of the soil in which 
they were grown.  Fruits, vegetables and drinking water do not provide substantial 
amounts of selenium (34).  In general, beef, white bread (made of high selenium wheat), 
pork, chicken and eggs are believed to account for about half of the selenium in diets of 
people in the United States (37).   
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Requirements for Iodine and Selenium in Humans 
 
Requirements for Iodine in Humans
Several international groups have made recommendations for iodine intakeswhich 
are fairly similar.  International Council for the Control of Iodine Deficiency Disorders 
(ICCIDD), WHO, and UNICEF recommend the following daily amounts:  age 0-7 years, 
90 µg; age 7-12 years, 120 µg; older than 12 years, 150 µg; and pregnant and lactating 
women,  
200 µg (38) 
A recent report by the Food and Nutrition Board, Institute of Medicine, National 
Academy of Sciences, USA, offers similar recommendations.  It calculates an "Estimated 
Average Requirement" and from that derives an RDA (Recommended Daily Allowance).  
However, occasionally sufficient data are not available and instead an Adequate Intake 
(AI) is stated which may be set higher than the RDA would be, for safety.  The 
recommendations are as follows:  the AI for infants 0-6 months is 110 µg iodine and 7-12 
months, 130 µg; the RDA's are:  1-8 year old, 90 µg; 9-13 years, 120 µg; 14 and older, 
150 µg; pregnancy, 220 µg; lactation, 290 µg.  The Food and Nutrition Board also sets 
the tolerable upper intake levels (UL) at 200 µg /day for children 1-3 years old, 300 
µg/day for children ages 4-8, 600 µg/day for ages 9-13, 900 µg/day for ages 14-18 and 
1100 µg/day for adults (39). 
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Requirements for Selenium in Humans
The recommended daily allowances are set for selenium for adolescent and adult 
men and women at 55 µg (35).  The RDA for pregnant women is 60 µg/day.  For 
lactating women it is 70 µg/day.  The UL for adolescents and adults is 400 µg regardless 
of pregnancy or lactating state.   
The adequate intake for infants from 0 to 6 months is 15 µg/day of selenium (2.1 
µg/kg).  The adequate intake for infant aged 7-12 months is 20 µg/day of selenium (2.2 
µg/kg).  The RDAs for children are 20 µg/day for ages 1-3 and 30 µg /day for 4-8 years.  
For children aged 9 to 13 years, it is 40 µg /day of selenium.  For children aged 14 to 18 
years, the RDA is 55 µg /day of selenium for both girls and boys (35).  The tolerable 
upper intake level (UL) for 0 to 6 month is 45 µg /day.  This value increases 
progressively to 280 µg/day for 13 year-old children (35).   
 
Indicators of Iodine and Selenium Status 
 
Indicators of Iodine Status
The pituitary gland responds to low levels of circulating thyroid hormones by 
increasing the secretion of its hormone, thyroid stimulating hormone (TSH), which drives 
the thyroid gland to enlarge, to increase iodine uptake from the blood and to produce 
more hormones.  Precisely assessed thyroid size is one of the most sensitive indicators of 
community iodine nutrition (40).  It is usually determined by palpation or by 
ultrasonography, the latter being more precise.   
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Urinary iodine concentration is currently the most practical biochemical marker 
for iodine nutrition in remote areas in the community (40).  Most iodine absorbed in the 
body eventually appears in the urine; therefore urinary iodine is a good marker of very 
recent dietary intake.  Urinary iodine values may not be reliable in areas where 
substantial amounts of goitrogens such as thiocyanate are ingested from the staple food, 
because goitrogens prevent the uptake of iodine by the thyroid gland and the subsequent 
thyroid hormone synthesis (29).  In this case urinary iodine may be normal but plasma 
TSH will be increased due to the lack of enough thyroid hormone feedback to the anterior 
pituitary (29). 
Plasma level of thyroid stimulating hormone (TSH) is the most sensitive 
functional indicator of iodine status (29, 41).  When dietary supplies of iodine are limited, 
stimulation of thyroid gland by increased plasma TSH may be enough to maintain 
circulating thyroid hormone levels.  It is only when the deficiency is severe that thyroid 
hormone levels begin to decline (29).  A blood spot of TSH in neonates is a valuable 
indicator of iodine nutrition (31).   
Thyroglobulin is the most abundant protein of the thyroid, providing the matrix 
for thyroid hormones synthesis.  Normally, small amounts are secreted or leak from the 
thyroid into the circulation (42).  When the thyroid is swollen or injured, larger amounts 
of thyroglobulin are released into the blood in response to thyroid stimulating hormone 
(42).  Iodine deficiency-related thyroid hyperplasia is associated with increased serum 
thyroglobulin.  In this case, serum thyroglobulin reflects iodine nutrition over months or 
years (40). 
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Determining serum concentrations of the thyroid hormones T4 and T3 is usually 
not recommended for monitoring iodine nutrition because these tests are more 
cumbersome, more expensive, and less sensitive as indicators at the community level 
(40).  The prevalence indicators of IDD and criteria for a significant public health 
problem are presented in Table I (adapted from (31)) 
 
Table I 
Prevalence indicators of IDD and criteria for a significant public health 
problem 
_______________________________________________________________________ 
 Variables                                          Normal          Mild             Moderate            Severe      
_______________________________________________________________________ 
Prevalence of goiter in 
school-age children 
(SAC) (%)                                         <5                 5-19.9              20-29.9                >30 
 
Frequency of thyroid volume  
in SAC >97th percentile by  
ultrasound (%)                                   <5                5-19.9               20-29.9               >30 
 
Median urinary iodine in 
SAC and adults (µg/L)                   100-200           50-99                20-49                  <20 
 
Frequency of neonatal  
TSH >5 µU/ml in whole 
blood (%)                                           <3                 3-19.9               20-39.9              >40 
_______________________________________________________________________ 
Indicators of Selenium Status
Assessment of selenium status can be done through a variety of means, including 
measurement of specific selenoproteins.  Estimation of dietary selenium intake, 
measurement of selenium concentration in blood, tissues, excreta, and determination of 
glutathione peroxidase activity in various blood components are the common techniques 
used for assessing selenium status (34).  Based on the observation of Keshan disease in 
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China where there is severe selenium deficiency, the occurrence of the disease in a 
population indicates that the population is selenium deficient (35).  Cellular and plasma 
glutathione peroxidases are the functional parameters commonly used for the assessment 
of long and short-term selenium status, respectively (29, 34).  However, plasma 
selenoprotein P concentrations appear to be more affected by selenium deficiency than 
glutathione peroxidase activity (35). 
Selenium in toenails reflects selenium intake from approximately 6 to 12 months 
before sample collection (43).  Selenium concentrations in hair are also considered as 
indicators of long-term selenium status.  However, the use of hair selenium as an 
indicator of status is limited because contamination of hair by selenium-containing 
shampoo may affect the selenium content of this tissue (35). 
 
Impact of Iodine and Selenium Deficiencies on Bone Health 
 
Kashin-Beck disease, a severe type of osteoarthritis, has been associated with the 
deficiency of iodine (3) and selenium (2, 4, 44).  Kashin-Beck disease (Osteoarthritis 
deformans endemica) is a degenerative, disabling endemic osteoarticular condition that 
affects the bone and joints of its sufferers, with a typical onset in the first or second 
decade of life (2, 26).  Kashin-Beck disease was first identified in 1849 by a Russian 
doctor, Nikolai Ivanovich Kashin, but its cause is still unknown.  In Tibet, the risk factors 
seem to include selenium deficiency in the soil (2), fungal contamination of barley (the 
staple grain) (45), organic matter (fluvic acid) in the water (2), and iodine deficiency (2, 
3, 46).  
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Kashin-Beck disease has been reported in certain areas of Tibet, northern China, 
Mongolia, Siberia, and North Korea (2, 33).  In China, 30 million people live in areas 
where the disease is endemic, and at least 2 to 3 million people are estimated to be 
affected (2).   
Initial symptoms of Kashin-Beck disease in pre-adolescents and adolescents 
include stiffness, swelling, and pain in the interphalangeal joints of the fingers.  Levander 
reports that the disease is reversible at this point (26).  As the disease progresses, 
generalized osteoarthritis occur in the elbows, knees, and ankles, with locking of joints 
often occurring in many cases by the third decade (26, 47).  Impaired bone development 
as a result of degeneration and necrosis of the bone’s epiphyseal growth plate has been 
suggested by Ge and Yang (48).  The joint and articular cartilage changes are the source 
of its alternate name in China, Dagujie disease or “enlarged joint” disease (26).  While 
selenium deficiency is accepted as a cause of the disease, all selenium deficient areas do 
not exhibit the disease, implicating other factors as necessary for full development of true 
Kashin-Beck disease.  Kashin-Beck disease has been suggested by Suetens and 
colleagues (49) to result from oxidative damage to cartilage and bone cells when 
associated with decreased antioxidant defense.   
Selenium deficient and fluvic acid supplemented mice, considered by Yang and 
colleagues (50) to be an animal model of Kashin Beck-disease, had irregular bone 
formation and substantial reduction in the number of lysine residues in type I collagen 
from bone and type II collagen from cartilage.  A lower melting point of type I collagen 
from bone, and lower breaking force of bone were also found in the animals.  In a study 
aiming to understand the role of selenium deficiency in the etiology of Kashin-Beck 
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disease, Sasaki and colleagues (51) observed decreased femur ash weight, and a decrease 
in the sulfotransferase activity (involved in glucosaminoglycan synthesis) in 3 to 11 
month selenium-deficient rats.   
Suetens and colleagues (52) also suggest a second mechanism whereby normal 
stimulation of bone remodeling by thyroid hormones may be blocked by certain 
mycotoxins in the fungal contaminated grain.  Chasseur and colleagues (45) did not 
observe a decrease in the prevalence of Kahsin-Beck disease by iodine supplementation 
when a fungal species (Alternaria sp.) was present, and thus suggested a competitive 
binding of a mycotoxin to a thyroid hormone receptor in bone cells.  Fluvic acid, an 
environmental contaminant involved in the etiology of Kashin-Beck disease, has been 





Arthritis refers to conditions affecting the joint and surrounding tissues.  The most 
common forms of arthritis are osteoarthritis (OA) and rheumatoid arthritis (RA) (12). 
 Osteoarthritis is a degenerative joint disease involving the hips, knees, neck, 
lower back, or hands that is prevalent in many parts of the world.  It results in pain, 
lameness, and disability (54).  OA usually develops in response to mechanical trauma 
from repetitive motion, from excess body weight, from heavy physical work or from high 
intensity sport performance (54, 55).  The trauma thins and degrades the cartilage that 
cushions the ends of the bones.  The bones then rub together, causing a grating sensation.  
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Reduced joint flexibility as well as swelling due to development of bony spurs 
(osteophytes) or an effusion caused by synovial fluid accumulation are also observed in 
OA (54)  This form of arthritis affects 12.1% of U.S. adults or 20.7 million people (12).  
Osteoarthritis was the second most common diagnosis, after chronic heart disease, 
leading to social security disability payments due to long-term absence from work (56). 
 In osteoarthritis the synovium has been shown to be inflamed with concomitantly 
increased production of interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α), 
interleukin-6 (IL-6), and interleukin 8 (IL-8) (57).  These cytokines induce the production 
of metalloproteinases that contribute to cartilage destruction (54, 57).  Risk factors 
include age, trauma, occupation, exercise, gender and ethnicity, genetics, obesity, and 
diet (54).  
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that involves 
peripheral joints in the hands, wrists, elbows, shoulders, knees, feet, and ankles.  It is 
characterized by a non-specific, symmetrical inflammation of peripheral joints, resulting 
in a progressive destruction of articular and periarticular joints and structures (58) as well 
as local bone loss (59).  Symptoms include pain, swelling, stiffness, deformity, and 
reduced mobility and function (12).  Agglutination tests are used to detect antibodies to 
altered gamma-globulins (rheumatoid factor) and immunoglobulin M (IgM) rheumatoid 
factor is found in about 70% of RA cases (58).  Osteoporosis is well recognized in RA.  
RA is associated with local and systemic bone loss with involvement of cytokines such as 
the RANK/RANKL system and TNF-α, which promotes local and systemic osteoporosis 
(10, 60).  
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The causes of arthritis including osteoarthritis and rheumatoid arthritis have not 
been completely elucidated.  Reactive oxygen species (ROS) such as superoxide radicals, 
hydrogen peroxide, hydroxyl radical and hypochlorous acid, as well as reactive nitrogen 
species (RNS) such as nitric oxide and peroxynitrite are believed to contribute 
significantly to tissue injury and the resulting inflammation in RA (61).  Cytokines such 
as IL-1, IL-6, TNF-α and cyclo-oxygenases are also implicated in the etiology of 
inflammatory joint disease, and diseases related to the bone loss, including OA and RA 
(62).  Prevention and treatment measures for RA include the use of non-steroidal anti-
inflammatory drugs (54), niacinamide (63), estrogen and 17-β estradiol (64), 




Osteoporosis, or porous bone, is a disease characterized by low bone mass and 
structural deterioration of bone tissue, leading to bone fragility and subsequent fracture, 
especially of the hip, spine and wrist, although any bone can be affected (66).  
Osteoporosis is a major public health problem for an estimated 44 million Americans, or 
55 percent of the people 50 years of age and older.  In the U.S, 10 million people are 
estimated to already have the disease and almost 34 million more are estimated to have 
low bone mass, placing them at increased risk for osteoporosis (17).  Of the 10 million 
Americans estimated to have osteoporosis, 80% are women and 20% are men.  
Osteoporosis causes more than 1.5 million fractures annually, including: approximately 
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700,000 vertebral fractures, over 300,000 hip fractures, 250,000 wrist fractures, and 
300,000 fractures at other sites (17). 
Risk factors for osteoporosis include, gender, age, family history, body size, 
ethnicity, hormone levels, inactivity, smoking, alcohol consumption, certain medications 
such as glucocorticoids and aluminum-containing antacids, hyperthyroidism, sex 
hormone deficiency, genetic factors, hyperparathyroidism, multiple myelanoma, 
transplantation, chronic kidney, lung, and intestinal diseases, and inadequate intake of 
calcium and vitamin D (67).   
Prevention and treatment options for osteoporosis include calcium and vitamin D 
supplementation, changes in diet and life style behaviors, exercise, estrogen replacement 
therapy, SERMs (selective estrogen receptor modulators) such as raloxifen and tibolone 
(68); bisphosphonates, calcitonin, and teriparatide (68). 
 
Relationship between Arthritis and Osteoporosis  
 
Even though some studies have shown an inverse association between 
osteoporosis and osteoarthritis (7), the occurrence of osteoporosis in osteoarthritic 
patients is well documented.  Hip OA was not associated with increased bone density in 
the femoral head or the neck of the femur in middle-age men (69).  Higher trabecular 
number accompanied with thinning and fenestration in dense cancellous bone areas of 
proximal tibia was observed in patients with OA (9), suggesting the trabecular bone in 
this region to be osteoporotic.  In the elderly, knee osteoarthritis was associated with 
increased risk of vertebral and non-vertebral fractures independent of bone density and 
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postural stability (19).  A lower modulus of elasticity was observed in the femoral neck of 
patients with OA compared to osteoporotic patients (70).  In OA, decreased mechanical 
strength of subchondral bone due to immature collagen fibers, decreases in proline cross-
links, and reduced mineralization has been reported by Bailey and colleagues (11).  A 
hallmark of osteoarthritis is the degeneration of joint cartilage.  The volume of tibia knee 
cartilage in older adults was positively associated with total body bone mineral density in 
men and women independent of age, BMI, tibia bone area, and physical activity (71).  
Forslind and colleagues (72) found a significant positive association between reduced 
bone mass and radiological joint damage in women with recent RA at baseline and after 2 
years, and they suggested a common mechanism for the development of bone loss and 
joint destruction. 
 
Indicators of Bone Quality 
 
Bone quality is defined as a set of characratics influencing bone strength (72).  
These characteristics include the structural properties (geometry and microarchitecture) 
and the material properties (collagen and mineral ), which are affected by turnover (72).   
Bone quality may be determined by several factors, including its properties that 
affect its strength.  The geometry of bone consists of the size and shape of bone.  The size 
of bone is a determinant of bone strength.  Reduced bone mineral content and smaller 
vertebral bone were seen in women with spinal fracture (74).  The structural arrangement 
of bone (microarchitecture) is also strongly related to bone strength (75)  
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Collagen content and structure also affect bone quality.  There is a reduced 
concentration of cross-links in bones from patients with osteoporosis (72).  Collagen has 
smaller influence on the stiffness of bone, but improves bone toughness through 
intramolecular cross-links (73).  Collagen fiber orientation explained 71% of variation in 
bone tensile strength in a linear regression analysis (76).  Bone is formed by the 
production of a protein framework that hardens when calcium and phosphorus are 
deposited on it.  Bone strength partly depends on this mineral deposition (76).  Apart 
from bone mineral content, the perfection and the maturity of mineral crystals are also 
important determinants of bone strength (76). 
 
Bone Mineral Density
Bone mineral density refers to the amount of minerals in a three-dimensional 
volume of bone.  However, bone mineral density is also measured by dual energy X-ray 
absorptiometry (DEXA) based on a two-dimensional area.  There is a strong correlation 
between fracture risk and low bone mass.  The WHO has developed diagnostic categories 
that compare a person’s bone density with the peak value for a healthy young adult  using 
a T-score (66).  A normal bone is indicated when bone mineral density or bone mineral 
content is within 1 standard deviation (SD) (+1 SD or -1 SD) of the young adult mean 
value.  A low bone density (osteopenia) is indicated by a bone mineral density or bone 
mineral content of 1 to 2.5 SD below the young adult mean (-1 to -2.5 SD).  Osteoporosis 
is defined by a bone density or bone mineral content of 2.5 SD or more below the young 
adult mean (>-2.5 SD).  Severe osteoporosis is said to exist when bone mineral density or 
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bone mineral content is more than 2.5 SD below the young adult mean and there have 
been one or more fractures due to osteoporosis (66). 
 
Bone Microarchitecture
Bone mass is not the only property that affects bone strength.  Bone microarchitecture 
is also a determining aspect of bone strength and an essential component affecting the 
assessment of bone mechanical properties (75).  Bone microarchitectural parameters such as 
trabecular thickness (TbTh,) trabecular number (TbN) , trabecular separation (TbSp), 
connectivity of the trabeculae, as well as width and porosity of the cortical bone seem to be 
determinants of bone fragility independent of bone density (77).  Trabecular number and 
thickness decrease in aging (74).  Silva and Gibson (74) developed an aged model of human 
vertebral trabecular bone by concurrently reducing the trabecular thickness and trabecular 
number of a young model with intact values.  The reduction of trabecular thickess and 
number of the bone led to a decreased modulus of elasticity and strength of the model.  When 
the bone mass of the aged model was restored by increasing the trabecular thickness, but not 
the trabecular number, the strength increased by 60%, but was still only 37% of its intact 
value, indicating that that a full recovery of bone strength requires a regeneration of the lost 
trabecular number (74). 
The structural model index (SMI) is a 3-D bone structural parameter that 
quantifies the plate versus rod characteristics of trabecular bone (78, 79).  An SMI of zero 
(0) pertains to a purely plate-shaped bone, and a value of 3 indicates a purely cylindrical 
rod-like structure, and values between designate mixtures of plate and rod forms (79).  
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Human tibial cancellous bone changes with aging from plate-like to rod-like, indicating a 
deterioration of the structure of bone with aging (78). 
Microarchitectural deteriorations such as decreased trabecular connectivity have 
been related to increased possibility of fracture and one of the positive effects of 
parathyroid hormone (PTH) on bone is the restoration of moderate lost trabecular 
connectivity (80).  Even though connectivity is believed to be important in the 
biomechanics of bone in osteoporosis (80), there is not much evidence to support this 
hypothesis in healthy bone.  Kabel et al. observed an inverse association of connectivity 
with bone stiffness (81).  Connectivity seems to be inversely associated with elastic 
properties of cancellous bone of people with no known bone disorders.   
Degree of anisotropy (DA) refers to the extent to which a material has different 
properties in different directions (82, 83).  Poor bones seem to have higher DA values.  
An analysis of porous hydroxyapatites with an anisotropic characteristic intended for the 
bone-graft market found the specimens to possess lower compressive moduli than 
isotropic specimens with the same apparent densities (84).  Similarly, Chappard and 
colleagues (83) found higher DA values in the bone of subjects with vertebral fracture 
than in control subjects.  Furthermore, an improvement in the structural properties of the 
vertebra (L1 and L2) of dogs following alendronate treatment was accompanied with a 
decreased degree of anisotropy in the bone specimens (85).  
 
Bone Biomechanical Properties
Biomechanical properties of bone are those properties of bone that are associated with 
elastic and inelastic reactions when a force is applied. They also involve the relationship 
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between stress and strain (86).  Examples of biomechanical properties of bone include all 
kinds of strength (compressive strength, tensile strength, and shear strength) and strain, 
modulus of elasticity (stiffness), hardness (86), and fatigue life (fracture of bone under 
repetitive stress) (86, 87).  Bone strength depends on bone matrix volume, bone 
microarchitecture, and the degree of mineralization of bone (88).  The more the cancellous 
bone is mineralized, the higher its stiffness. Young human bone is less mineralized than 
mature bone (88).  Ciarelli and colleagues (89) suggest that both low and high mineralization 
may be detrimental to bone mechanical properties, with low mineralization levels causing 
reduced stiffness and strength and high mineralization leading to reduced fracture toughness 
due to increased brittleness. 
Bone mechanical properties can be determined using three or four point bending 
techniques and fatigue tests for long bones (82, 87, 90).  The compressive tests are more 
appropriate for small and cubic samples of trabecular bone (88).   
There is not much information about the effect of iodine and selenium on the 
biomechanical properties of bone in growing individuals.  However, retarded growth and 
lower breaking force of the tibia have been observed in selenium-depleted mice compared to 
the controls (50).  Growth retardation and osteopenia were seen in second generation 
selenium-deficient male rats (4).  Methamizol-induced hypothyroidism during postnatal 
development leads to decreased bone length and biomechanical competence (measured as 
Vickers microhardness) of the femurs and humeri in birds (20).  
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Biochemical Markers of Bone Metabolism
Bone density determination is valuable for evaluation of patients at risk for 
osteoporosis, but it does not give any information about the rate of bone turnover, 
therefore, supplementing bone density information with measurement of markers of bone 
turnover may enhance the prediction of fracture risk.  Bone markers indirectly measure 
bone cell activities (79).  Biochemical markers of bone metabolism are byproducts that 
are released into the blood stream and urine during the process of bone remodeling, 
which involves bone resorption and bone formation (91).   
Serum and urine tests can detect these markers and provide information about the 
rate of bone resorption and formation.  Bone formation can be evaluated using serum 
non-specific alkaline phosphatase (ALP), bone-specific alkaline phosphatase (B-ALP), 
osteocalcin, carboxyterminal propeptide of type I collagen (PICP), and aminoterminal 
propeptide of type I collagen (PINP) (91).  Indicators of bone resorption such as cross-
linked C-telopeptide of type I collagen, tartrate resistant acid phosphatase (TRAP), N-
telopeptide of collagen cross-links (NTx), and C-telopeptide of collagen cross-links 
(CTx) can be determined in serum.  Other bone resorption markers such as 
hydroxyproline, free and total pyridinoline, free and total deoxipyridinoline as well as 
NTx and CTx can be assessed in urine (91).   
Bone specific alkaline phosphatase is an osteoblast product that is believed to be 
an essential enzyme for bone mineralization (91).  Both bone specific and tissue non-
specific alkaline phosphatase can promote mineralization by hydrolyzing a variety of 
phosphate compounds to make inorganic phosphate available for bone mineralization 
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(92).  It has also been suggested that alkaline phosphatase may destroy inhibitors of 
mineral crystal growth and behave like a calcium binding protein (93).   
Osteocalcin (bone gla-protein) is a peptide synthesized and secreted by 
osteoblasts during bone formation.  It is mostly incorporated into bone matrix with some 
escaping into the blood; therefore, osteocalcin is accepted as a marker of bone formation.   
However, osteocalcin is also released from bone to the circulation during bone resorption.  
Therefore osteocalcin is more a marker of bone turnover than of bone formation (91). 
Amino-teminal and carboxyterminal propeptide of type I collagen direct the 
assembly of the collagen triple helix and are separated from the newly formed collagen 
molecules and released into the circulation (94).  Therefore, their concentration in serum 
may be an index of bone formation.  However these byproducts of collagen synthses are 
also produced by other type I collagen-containing tissues such as the skin (94).  Serum N-
terminal and C-terminal propeptide of type I collage are less useful than ALP and OC as 
indicators of bone formation (94)  
TRAP (tartrate resistant acid phosphatase, also known as type-5 acid phosphatase) 
is an iron-containing protein produced in different tissues with acid phosphatase activity 
and is one of the most abundant enzymes in osteoclasts (95).  Serum TRAP is used as a 
biochemical marker of osteoclastic activity and bone resorption (96).  However, it lacks 
specificity because other cells that are not related to bone such as erythrocytes and 
platelets also release TRAP into serum (96). 
NTx and CTx are degradation products of type I collagen, mainly produced by 
cathepsin K.  Pyridinoline, deoxypyridinoline, and cross-linked C-telopeptide of type I 
collagen (ICTP) are also degradation products produced by matrix metalloproteases (97).  
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Pyridinoline and deoxypyridinoline are the two cross-links present in the mature form of 
type I collagen.  Urine levels of pyridinoline and deoxypyridinoline correlate with the 
breakdown of collagen released from bone matrix by the osteoclasts (98).  This cross-
linking structure, which is unique to collagen and elastin molecules, creates bonds 
between polypeptide chains in collagen fibrils to enhance stability.  Pyridinoline and 
deoxypyridinoline cross-links can be excreted free or still bound to the peptide chains and 
either form can be measured.  Deoxypyridinoline is the more abundant cross-link in bone 
collagen and is generally the one measured (98).  
 
Factors that Influence Bone Quality 
 
There are several factors that may influence bone quality.  Those factors include 
gender (99), age, family history, ethnicity, hormone levels, nutrition (17), the use of some 
drugs, and some chronic diseases.  However, the discussion in this study is limited to how 
bone quality is affected by gender, growth hormone levels, and selected dietary factors. 
 
Gender
Women are at more risk for poor bone status because they have lighter bone, 
thinner bones and lose bone rapidly after menopause (12).  Even though osteoporosis is 
more common in old women than men, Baxter-Jones and colleagues (99) found the sex 
difference in adolescents’ bone mineral content (BMC) to be debatable as the difference 
is generally explained by anthropometric difference.  These authors found no difference 
between boys and girls aged 8-19 years old with respect to BMC in the spine.  The higher 
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BMC in males despite a significance of P<0.05, they considered to be less than the 
measurement error.  Jarvinen et al. (100) observed a lower responsiveness to mechanical 
loading and higher bone density in female than male rats at puberty, and they suggested 
that estrogen causes deposition of an extra stock of minerals in female bone at this age 
and that this extra condensation of female bone seems to persist in adulthood in rats.  
Similarly, a longitudinal study of Canadian children showed a higher cross-sectional area 
(an index of bending strength) of the femoral neck in boys before peak height velocity 
(PHV), but for girls, the cross-sectional area was higher after PHV (101).  After 
menopause, there is a greater decrease in trabecular volumetric bone mineral density in 
women than men at central sites but they are similar at peripheral sites (102).   
 
Growth Hormone (GH)/Insulin-Like Growth Factor 1 (IGF-1)
Normal growth and development in young mammals depends on many factors 
including growth hormone (GH), thyroid hormones and nutritional status. The growth 
promoting effect of GH is believed to be mediated in part by IGF-1 (103).  Growth 
hormone causes the liver (and to a less extent other tissues) to produce several small 
peptides called somatomedins (at least four somatomedins have been isolated), that in 
turn have potent effects of increasing all aspects of bone growth (104).  The most 
important of these is somatomedin C, also called IGF-1, which in turn regulates GH 
secretion through a feedback stimulation of somatostatin (103).  Both growth hormone 
and IGF-1 influence bone growth and increase bone mineral content and bone mineral 
density (105).  The African pygmies have a congenital inability to synthesize enough 
IGF-1 and have reduced amounts of plasma IGF-1, while their plasma GH is either 
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normal or high (104).  This might account for the short stature of these people.  The 
bioavailability and bioactivity of IGF-1 is modulated by IGF-binding protein-3 (IGFBP-
3), a GH dependent glycoprotein and the main carrier for IGF-1 in blood (103).   
Yanovski and colleagues (105) investigated bone status and the levels of IGF-1 
and IGF binding proteins in white and African American girls and found BMC, BMD 
and free IGF-1 to be higher in African American than white American girls, while IGF-
binding protein-3 was similar or lower in African American girls.  In the study, free IGF-
1 was positively correlated with BMC and BMD in both groups. 
 
Nutrition
Several nutritional and dietary factors have been shown to influence bone health.  
Some of the minerals that influence bone quality include calcium (67), phosphorus (106), 
magnesium, zinc (107), iron (108), copper (109), manganese (110), iodine and selenium 
(3-5, 18).  Some of the vitamins associated with bone status include vitamin K (111, 
112), vitamin D, vitamin C (106), and vitamin E (113).   
In OA, cartilage degeneration is associated with inflammation of the synovial 
membrane and the release of reactive oxygen species (114).  Therefore, vitamins and 
minerals as well as some food-derived phytochemicals exhibiting antioxidant properties 
are believed to have important roles in the prevention and treatment of the disease.   
Vitamin C is necessary for collagen cross-linking, and bony defects are 
recognized as a part of the scurvy syndrome due to a weakening of the collagenous 
structure of bone (107).  Vitamin C along with other antioxidants may protect bone 
against oxidative stress from smoking.  High intake of vitamins C and E (but not β-
carotene and selenium) decreased the odds ratio of hip fracture in current smokers (115).  
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Bone abnormalities associated with scurvy are believed to be caused by an impairment of 
hydroxylases that catalyse vitamin C dependent hydroxylation of prolyl and lysyl 
residues, important steps in collagen synthesis prior to the crosslinking of collagen 
molecules by the copper-dependent lysyl oxidase (116).   
Lathyrism is a crippling disease originating from the consumption of some plant 
species (e.g. lathyrus sativus) containing toxic compounds (117).  Defects in the 
synthesis of collagen due to inhibition of lysyl oxidase, a copper dependent enzyme, have 
been suggested as a cause of bone deformity accompanying the disease (118).  Vitamin C 
administration reduced serum cytokines and improved collagen structure in rats with 
experimentally induced lathryrism (118). 
Vitamin E and 17β estradiol are believed to accumulate in plasma membranes and 
to decrease membrane fluidity leading to protection against lipid peroxidation (119).  
Vitamin E in physiological doses prevented chondrocyte lipid peroxidation and cartilage 
matrix protein degeneration in rabbit chondrocytes treated with hydrogen peroxide and 
lipopolysaccharides (113).  Vitamin E treatment decreased thiobarbituric acid reactants 
(TBARS) release from cultured bovine articular chondrocytes exposed to hydrogen 
peroxide (119).  The combination of selenium as sodium selenite with vitamin E and 
vitamin C completely restored the structural alteration of long bone tissues in an 
osteoporotic rabbit model, while a complete restoration was not possible using the 
combination of only the two vitamins (120).  Some dietary factors such as the 
consumption of food containing phytochemicals with antioxidant properties or having 
estrogen-modulating activities such as soy protein 
and soy isoflavones (121-125) have been shown to improve bone quality. 
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Prevention and Treatment of Osteoporosis and Osteoarthritis 
 
Prevention and treatment options for osteoporosis consist of changes in diet and 
lifestyle, as well as the use of drugs and hormones that act by inhibiting osteoclast-
mediated bone resorption.  To date, most of the drug and hormone options have some 
serious health-damaging side effects.  The treatment and prevention options include 
calcium and vitamin D, changes in diet and life style behaviors, exercise, and medications 
such as estrogen, raloxifene (a selective estrogen receptor modulator or SERM), 
bisphosphonates (such as alendronate, residronate, and zoledronate), calcitonin, and 
teriparatide, (68, 126).  Both calcium and vitamin D are commonly used in the treatment 
of osteoporosis.  Although neither calcium nor vitamin D alone has been shown to 
prevent osteoporosis in postmenopausal women, the combination is beneficial (68).  
Estrogen reduces the incidence of fracture (126).  In animal models, estrogen deficiency 
leads to an increase in osteoclast formation and bone loss.  Inhibition of 
osteoclastogenesis is the major means by which estrogen prevents bone loss through 
diminishing the production of interleukin-1, interleukin-6, and TNF-α (127).  However, 
estrogen increases the incidence of coronary artery diseases, stroke, breast cancer, and 
thromboembolic phenomena (126).  Raloxifene, a SERM, which has been shown to 
prevent bone loss and fracture in postmenopausal women, inhibits growth of uterine 
tissues and decreases the incidence of breast cancer, but still increases the incidence of 
thromboembolic events (128).  Calcitonin, via its receptor, inhibits osteoclastic bone 
resorption.  However, calcitonin downregulates calcitonin receptor, and this may reduce 
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its effectiveness (129).  Bisphosphonates act by inactivating osteoclasts to increase bone 
mineral density and prevent fracture, whereas long-term treatment with bisphosphonates 
causes microdamage accumulation and increased susceptibility to fracture in dogs (126).   
The agents that have been used in some clinical trials as new or alternative drugs 
for the treatment of osteoporosis include androgens, growth hormone, insulin-like growth 
factor-1, and strontium ranelate.  The drugs that are being developed to inhibit bone 
resorption include the OPG/RANKL/RANK system and cathepsin K inhibitors, 
vitronectin receptor antagonists, cytokines and growth factors.  New drugs to promote 
bone formation include the commonly used lipid-lowering statins and parathyroid 
hormone (PTH) (Teriparatide 1-34) (68).  Parathyroid hormone is approved for the 
treatment of osteoporosis in men who are at high risk of fracture (17).   
Other new drugs that are under investigation to treat bone-resorption diseases 
include the inhibitor of avB3 integrin, an adhesion receptor that mediates attachment of 
osteoclasts to bone surface, and osteoprotegerin (OPG) (126).  A single dose of OPG for 
two to three months to postmenopausal women inhibited both differentiation and 
activation of osteoclasts, and inhibited bone resorption in the women (130).  
 Prevention and treatment options for arthritis include exercise, diet, and the use 
drugs with analgesic and/or anti-inflammatory properties.  The drugs used include 
paracetamol (54), estrogen (64), methotrexate (MTX), glucocorticoids (12), non-steroidal 
anti-inflammatory drugs (NSAIDs), and cyclo-oxygenase-2 (cox-2) selective inhibitors 
(54).   
 Methotrexate (MTX), a folate antagonist, is used in the treatment of RA but 
treatment is often discontinued because of side effects due to folate antagonism (65).  
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Whittle and Hughes propose that folic acid supplements be prescribed routinely to all 
patients receiving MTX.  They recommend a dosing schedule of 5 mg of oral folic acid 
given on the morning following the day of MTX. 
 Glucocorticoids may cause a secondary osteoporosis that can be alleviated by 
bisphosphonate treatments (68), but these have their own adverse effects with long term 
treatment as mentioned earlier in this section.  Cox-2 selective inhibitors are believed to 
increase the risk for myocardial infarction (54).  
Most of the treatment options for both arthritis and osteoporosis have serious side 
effects (54).  Therefore scientists are still looking for safe and efficient alternatives. 
The effects of iodine and/or selenium on bone are being investigated for the same 
reason of finding efficient, safe and sustainable solutions for bone diseases.  Potential 
links between iodine and/or selenium deficiencies and bone health have not been 
extensively studied.  The following section presents some of the existing literature on the 
effects of iodine and/or selenium on bone. 
 
Effects of Iodine and Selenium on Bone  
 
Effects of Iodine on Bone
The best known role of iodine in mammals is for the synthesis of thyroid 
hormones.  Before puberty, thyroid hormones may be the major hormone required for 
normal maturation of bone (131).  Thyroid hormone (T3) is an important determinant of 
postnatal somatic growth and skeletal development and a primary regulator of bone and 
mineral metabolism in the adult (132-133).  Untreated childhood hypothyroidism leads to 
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profound growth retardation and delayed bone maturation.  Linear growth is almost 
completely stopped, but can be resumed quickly by replacement of thyroid hormones to 
produce a rapid catch-up growth (131).  In contrast, whereas thyrotoxicosis in children is 
associated with increased bone turnover and an accelerated growth rate, the advanced 
skeletal maturation that also occurs may lead to short stature (134) 
The mechanism whereby iodine and selenium may affect bone is not clear. 
However, delayed bone maturation has been observed in sheep fed iodine-deficient diets 
(135).  Thyroid hormone (T3) is believed to stimulate bone mineralization and cartilage 
matrix proteoglycan production (30).  T3 stimulates production of IGF-I in human 
osteoblasts (136) and plasma IGF-1 regulates bone growth and density in mice (137).  
Lower serum levels of IGF-1 and IGF-binding protein-3 were found in children living in 
an area of severe iodine deficiency compared to children living in an area with mild 
iodine deficiency (138).  On the other hand, hyperthyroidism is believed to cause bone 
loss by mechanisms that involve uncoupling of osteoblast and osteoclast activities (30).  
This indicates that normal bone turnover requires a physiological euthyroid status.  More 
studies involving patients with thyroid hormone resistance, cell culture studies, and 
molecular studies have shown that thyroid hormones have important effects on skeletal 
growth and development. 
Studies of Bone in Patients with Thyroid Hormone Resistance. The study of 
resistance to thyroid hormone (RTH) offers confirmation of the importance of T3 for 
skeletal growth and development.  RTH is a condition caused by a mutation in thyroid 
hormone receptor β gene (T3 receptor α is normal in all cases) that generates receptors 
which display impaired responses to T3 (131).  The condition is characterized by different 
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degrees of tissue hypothyroidism in the presence of increased free T4, free T3, and TSH 
(131).  Short stature occurs in 16% of affected children with delayed bone maturation in 
47% (134).  However, it is also believed that 84% and 53% of the children respectively 
have normal growth and bone maturation.  The reason for this variability is partly 
explained by some genetic evidence suggesting fundamental roles for both thyroid 
hormone receptor α and β during growth and skeletal development.  This genetic 
evidence is elaborated in the following section. 
Studies of Genetically Modified Animal Models. In TR-α (thyroid hormone 
receptor alpha) knockout mice, there is growth arrest and delayed bone maturation, with 
disorganization of epiphyseal growth plate chondrocytes, fewer hypertrophic cells in the 
growth plate, and delayed cartilage mineralization and bone formation (30, 139).  The 
growth arrest and delayed bone maturation were reversed after T3 replacement of 
1µg/day for one week (139).  In contrast, in T3 receptor β knockout mice, there is 
disruption of the pituitary-thyroid feedback axis and profound hearing loss, but little 
effect on skeletal development and growth (140).  Harvey and colleagues (30) agree and 
suggest that TR-α1 knockout mice lack expression of TR-α1, but TR-α2, and TR-β are 
maintained and the skeletal development is normal.  This suggests that TR-β is functional 
in bone in the absence of TR-α1. The combination of TR-α1 and β mutations to produce 
TR-α1 and β double knockout mice resulted in growth retardation and delayed bone 
maturation (141).  The TR-α1 and β double knockout mice also have been shown to be 
growth hormone and IGF-1 deficient (30).  Growth hormone (GH) replacement reverses 
some of the growth retardation but does not affect the defective ossification (142), 
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indicating that T3 may exert direct effects on growth plate chondrocytes in addition to 
effects that may be mediated by GH and IGF-1 (142). 
Thyroid Hormone in Cell Culture Studies. There is evidence documenting the 
expression of T3 receptors in osteoblasts, chondrocytes, and osteoclasts indicating that 
direct T3 effects on skeleton are important (30, 131).  Cultured human fetal epiphyseal 
chondrocytes have been shown to possess specific nuclear binding sites for T3 with 
appropriate binding affinities in the nanomolar range (143).  These cells respond to T3 in 
vitro with increased alkaline phosphatase activity after nine days of treatment.  Similarly, 
treatment of rat epiphyseal chondrocytes with T3 in vitro for 96 hours increased alkaline 
phosphatase activity and IGF-1 receptor mRNA expression, in addition to decreasing cell 
proliferation (144).  Thyroid hormone receptors are expressed at sites of 
intramembranous and endochondral bone formation in a variety of species.  Thyroid 
hormone receptor α1, α2, and β1 mRNA and proteins are expressed in osteoblasts and 
osteocytes and in reserve and proliferative zones of epiphyseal growth plate chondrocytes 
(30).  High affinity nuclear-binding sites for T3 and thyroid hormone receptor mRNA and 
proteins have been identified in primary cultured osteoblasts, osteoblastic bone marrow 
stromal cells, and growth plate chondrocytes (30).   
T3 receptors in human osteoblasts and osteoclasts at sites of active bone 
remodeling have been demonstrated by immunohistochemistry (145).  This may suggest 
that both osteoblast and osteoclast activities are affected by abnormalities in thyroid 
status leading to an imbalance in bone turnover.  It has been suggested that rat, mouse, 
and human osteoblasts are primary T3 target cells and that osteoclast responses may be 
secondary, or coupled to these primary T3 actions on osteoblasts (131).  T3 has also  been 
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shown to stimulate osteoclastic bone resorption, but this effect is believed to be mediated 
by T3-responsive osteoblasts as osteoclasts probably do not express functional thyroid 
hormone receptors (30).  T3 may stimulate osteoclastic bone resorption through the 
stimulation of the production of IL-6 and IL-8, cytokines that have been implicated in 
osteoclast synthesis and function (146).   
Studies using chondrocytes from different species showed that T3 regulates 
chondrocyte proliferation and the organization of chondrocyte columns, promotes 
terminal hypertrophic differentiation and induces calcification of cartilage matrix (30).  
The induction of terminal hypertrophic chondrocyte differentiation by T3 may be by 
promoting the expression of cyclin-dependent kinase inhibitors, which could stop cell 
cycle progression of proliferating chondrocytes to facilitate the onset of terminal 
differentiation (30).  Williams and coworkers (131) suggest that T3 may induce terminal 
hypertrophic chondrocyte differentiation by inhibiting the expression or the action of 
Indian hedgehog (Ihh) and Parathyroid/Parathyroid hormone related peptide 
(PTH/PTHrP) receptor both of which act as signaling molecules to maintain chondrocyte 
proliferation and delay hypertrophic differentiation, and both of which are considered as 
potential T3 target genes in the epiphyseal growth plate (147).  The prehypertrophic 
chondrocytes that are committed to the hypertrophic phenotypes express and secrete Ihh, 
which regulates the rate of hypertrophic differentiation (131).  Ihh acts directly on cells 
within the adjacent perichondrium to stimulate the production and release of PTHrP.  
PTHrP is secreted and acts (via its receptor) on prehypertrophic uncommitted 
proliferative chondrocytes to maintain cells in a proliferative state and to delay or inhibit 
the onset of hypertrophy (131, 147). 
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The terminal differentiation of proliferating chondrocytes into hypertrophic cells 
is the primary event that characterizes endochondral ossification and linear growth.  An 
increase in hypertrophic cell volume correlates with both the rate of long bone growth 
and the associated mineralization of cartilaginous matrix (131).  Williams, Robson, and 
Shalet (131) proposed the following mechanism involving GH, IGF-1, and T3 during 
endochondral ossification:  Growth hormone stimulates differentiation of resting zone 
chondrocyte precursor cells, IGF-1 stimulates their subsequent clonal expansion, and T3
terminates the clonal expansion and induces the terminal hypertrophic chondrocyte 
differentiation.  As the epiphyseal growth plate is sealed by a mineralized bone marrow 
(148), it is also possible that T3 plays an important role in promoting vascular invasion 
and osteoblast migration to facilitate new bone formation (30) 
Hypothyroidism in rats causes growth retardation due to growth plate dysgenesis 
in which hypertrophic chondrocyte differentiation does not continue (30).  There are also 
abnormalities in growth plate structure with abnormal proliferating chondrocyte columns 
and cartilage matrix, as well as impaired vascular invasion of the primary spongiosium 
(149). 
 
Effect of Selenium on Bone
Selenium is required for T3 synthesis and thyroid hormone homeostasis (24).  
Therefore it may indirectly protect bone through thyroid hormones.  Physiological doses 
of selenium may also directly protect bone through its antioxidative properties.  Selenium 
is an essential component of the enzyme glutathione peroxidase as well as thioredoxine 
reductases at the active center of which selenium catalyzes reduction of hydroperoxides 
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produced from oxidized species such as superoxide and lipoperoxides (150).  Thus, it 
may protect bone and cartilage cells against oxidative damage (151).  Dreher and 
colleagues (151) demonstrated a selenite-dependent GSH-Px mediated antioxidative 
defense of fetal human osteoblasts against hydrogen peroxide and reactive oxygen 
species.  In the study it was shown that osteoblasts express an antioxidative system to 
protect themselves against H2O2 after bone resorption is mediated by osteoclasts.  
Therefore lack of GSH-Px may lead to impaired osteoblast function and could be 
involved in metabolic bone diseases.   
Selenium in Cell Culture Studies. One of the proposed mechanisms for the 
protective effects of estrogen on bone is through the augmentation of oxidant defense to 
lower the concentration of reactive oxygen (ROS) species within bone cells (152).  ROS 
in high concentrations not only damage many cell constituents, but also affect many 
signaling proteins such as TNF-α and NF-kβ which are essential for osteoclasts at levels 
considerably lower than those that cause injury (152).  Cytokines such as IL-1 up-
regulate their own activity by inducing the production of oxidants that may inhibit 
cytosolic enzymes.  Selenium as an essential component of glutathione peroxidases and 
thioredoxin reductases helps keep cytosolic enzymes in their reduced form, therefore 
adequate selenium nutrition may protect bone by down-regulating cytokine signaling 
(63). 
Selenium in Epidemiological Studies. Selenium concentrations are relatively low 
in the serum of patients with RA when compared with healthy controls.  Plasma selenium 
levels were significantly (<0.001) lower in patients with RA than in normal, healthy 
controls (153).  Oxidative stress as measured by the levels of lipid peroxidation products 
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such as hydroxiperoxides and thiobarbituric acid reactive substances (malonaldehyde also 
called malondialdehyde) are elevated in the synovial fluid and serum from patients with 
RA with a concomitant decrease of plasma antioxidants (vitamin E and β-carotene) (154).  
Kashin-Beck disease has been suggested to result from oxidative damage to cartilage and 
bone cells when associated with decreased antioxidant defense (52).  Kamanli and 
colleagues (155) found lower concentrations of plasma GSH-Px, catalase, glutathione, β-
carotene, and vitamin E in patients with RA as compared with the controls.  In the same 
study, significantly higher concentrations of C-reactive protein, lipid peroxidation 
markers, and rheumatoid factor were found in patients with RA than in controls.  
Selenium in Human Intervention Studies. Even though selenium seems to be 
important in the prevention and treatment of bone diseases in animal models, most of the 
human intervention studies with selenium have not shown beneficial effects of selenium 
supplementation in preventing bone diseases.  A selenium-containing organic compound 
called PZ51, which has a GSHPx-like effect in catalyzing glutathione-dependent 
reduction of hydroperoxides, has anti-inflammatory activity (150).  Ebselen A, another 
selenium containing compound has been shown to block IL-1 mediated proteoglycan 
degeneration, and to reduce prostaglandin E2 (PGE2) release from the cartilage culture of 
bovine nasal septa (156) 
However, Peretz and coworkers (157) did not find any clinical benefits of 
selenium supplementation on 55 patients with moderate RA in a double blind, placebo-
controlled trial.  The authors suspected a placebo effect (that could be explained by an 
improvement in both groups of patients and controls) on the intervention trial.  In 
addition, selenium supplementation with normal or slightly increased intakes of Se had 
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no effect on serum levels of somatotropin (growth hormone), IGF-1, and IGF binding 
proteins 1 and 3 in healthy women (158).  Moreover, Moreno-Reyes and colleagues 
(2003) did not find any beneficial effect of selenium supplementation for 12 months on 
established Kashin-Beck disease in rural Tibetan children (5-15 year old) after iodine 
deficiency was corrected.  Similar results had been found by Tarp et al. (159) in a long-
term selenium supplementation of RA patients and controls with selenium.  In Tarp’s 
study, even after 26 weeks of treatment, patients with RA had granulocyte GSHPx 
activity significantly lower than those of controls, regardless of the nutritional selenium 
status.  The unresponsiveness of granulocyte GSHPx to selenium supplementation has 
been suggested to explain the predominantly negative effect seen with selenium in 
patients with RA (150).   
Selenium Studies in Animal Models. Selenium deficiency has been shown to 
decrease plasma osteocalcin, plasma IGF-1, bone mineral density and bone mineral 
content of growing male rats (4).  Dietary vitamins (E, C, A, B6, B2) and selenium led to 
a significant increase in the expression of GSH-Px and Cu/Zn-superoxide dismutase in 
the articular cartilage and the synovium, and a significant decrease in incidence of 
mechanically-induced osteoarthritis in STR/1N mice (28).  Ebselen, a novel organo-
selenium coumpound that catalycally inactivates peroxides in vitro in a manner similar to 
that of GSH-Px, has been found to inhibit peroxide-dependent inflammation.  It also 
inactivated leukotriene B4 generated by pig leukocytes in vitro by isomerizing the 
eicosanoid to its biologically inactive 6-trans isomer (160).  The authors also suggest that 
ebselen was an effective inhibitor of monoarthritis induced in mice with amidated 
glucose oxidase.   
42
However, excess selenium caused reduced production of IGF-1 (somatomedin C) 
and growth retardation in young rats (161).  Selenium treatment (3.3 mg sodium selenite 
per liter of drinking water for 35 days induced a significant reduction in circulating IGF-I 
and a significantly shorter tibia length in male rats (162).  Both selenium deficiency and 
selenium toxicity for 12 to 14 weeks led to a decreased stiffness (modulus of elasticity 







The methodology section of this paper consists of presentation of an experimental 
design involving the dietary manipulation of male and female rats as well as the 
determination of the effect of iodine and/or selenium status.  It also shows the assessment of 
growth, biochemical, physical, microarchitectural, and mechanical properties of the bone of 
rats and lipid peroxidation status of the rats.  A statistical analysis of main outcome 
measures ends the section. 
 
Animal Experiment and Study Design
Animal Feeding and Handling. Fourteen Sprague Dawley pregnant rats (120 g to 
186 g) were ordered from Harlan Teklad, (Indianapolis, IN) and fed an adaptation diet (low 
iodine, low selenium) for the last 5 to 7 days of pregnancy and a week of lactation.  Then 
the lactating dams were randomly assigned to four experimental diets: adequate selenium, 
adequate iodine (+Se+I); adequate selenium low iodine (+Se-I); low selenium, adequate 
iodine (-Se+I); low selenium, low iodine (-I -S) as indicated in Table I.  The experimental 
design is illustrated in Figure 1. Dams were assigned to the experimental diets one week 
after delivery.
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At three weeks of age, nine male and nine female pups per dietary treatment were 
randomly selected and continued on the diets of their respective mothers for seven more 
weeks.  The pups were fed ad libitum with free access to reverse osmosis water.  During 
the feeding experiment, two pups (one male and one female) died from the group 
consuming low iodine, adequate selenium diet.  The male died of an unknown cause at the 
vivarium during the 6th week and the female died in our laboratory during the anesthesia 
during the 7th week at the end of the experiment.  Thus the total number of pups remaining 
for the experiment was 70.  The use of rats in this study was approved by the Institutional 
Animal Care and Use Committee (IACUC) of Oklahoma State University (see the approval 
form in Appendix A) 
 
Adaptation Diet (-Se-I) Last 5-7 days 
 14 Sprague Dawley pregnant rats                          of pregnancy  
 & 7 days of 
 lactation 
 







M = Male, F = Female 
 














9 M 9 F 9 M 9 F 9 M 9 F 9 F9 M
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Preparation of the Experimental Diets. The experimental diets followed the 
recommendations of the American Institute of Nutrition (AIN) for growing rodents (163), 
(see table II) with some modifications.  The diets were isocaloric and isonitrogenous.  
Because casein is contaminated with some selenium, torula yeast was used as protein 
source instead of casein while correcting for the amount of carbohydrate provided by torula 
yeast.  Cornstarch was replaced with dextrose to make the diets more palatable for the rats.  
Minerals and vitamins were equivalent for the four different diets, except for iodine and 
selenium, which were either added or not added according to whether the diet was 
 
Table II: 
Composition of the experimental diets (g/kg diet) 
 






Mineral mix +I+Se 
Mineral mix +I-Se 
Mineral mix -I +Se 
Mineral mix -I-Se 



















































I = Iodine.  Se = Selenium. (+I+Se) = Adeaute iodine, adequate selenium.  (+I-Se) = Adequate iodine, low 
selenium.  (-I+Se) = Low iodine, adequate selenium.  (-I-Se) = Low iodine, low selenium. 
 
adequate or low in iodine and/or selenium.  Potassium iodate and sodium selenate were 
used as sources of iodine and selenium respectively.  The mineral mix was 
made in the Nutritional Sciences laboratory at Oklahoma State University following the 
recommendations of the AIN for growing rodents.  The composition of the mineral mix is 
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presented in Appendix B. The vitamin mix formulated according to the recommendations 
of AIN (Cat # 40060) was ordered from Harlan Teklad (Madison, WI) and kept refrigerated 
until diets were mixed.  The diets were mixed in batches of 5 kg in a mixer.  Diets were 
kept refrigerated and pups continued to be fed daily the diets of their mothers for 7 weeks 
after weaning, after which they were necropsied.  
Necropsy of the Pups. The day before the necropsy, the pups were put in individual 
metabolic cages and fasted overnight for a 12-hour urine collection.  On the day of 
necropsy, the urine volume of the rats was measured and recorded.  Then the rats were 
anesthetized with intraperitoneal injections of mixed ketamine (75mg/kg body weight) : 
xylazine (10mg/kg body weight), and weighed while they were sleeping.  Blood was drawn 
from their abdominal artery before dissecting them for the collection of other tissues.  
Blood was first kept on ice and then centrifuged at 8,000 rpm for five minutes to separate 
serum that was stored at -20°C.  Urine samples were also stored at –20°C.  A portion of the 
liver was quickly collected, weighed and put in liquid nitrogen before being stored at -
70°C.  The other portion of the liver as well as the heart were weighed and kept at -20°C.  
The thyroid gland and spleen were weighed and discarded.  The left leg (left femur and the 
left tibia together) were excised and kept in -20°C.  The right femur and tibia were isolated, 
cleaned, and frozen at -20°C.  The vertebral column was also excised and kept at -20°C. 
 
Determination of Weight Gain, Organ Weight, and Body Lean and Fat Mass. 
Weight gain was assessed by subtracting the weight of the rat recorded on the day 
of the start of the experimental diet from the weight recorded on the day of necropsy.  
Thyroid weight was determined by directly excising the thyroid gland and weighing it at 
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the time of the necropsy.  Other organs such as liver, heart and spleen were also excised 
and weighed.  The body lean and fat weights were assessed using DEXA.  In this 




To ascertain the iodine status of the rats, thyroid weight, serum thyroxin (T4) and 
serum triiodothyronine (T3) were assessed.  Serum T4 and T3 were assessed in the pups 
using radioimmunoassay (RIA) kits (Diagnostic Products Corp., Inc, Los Angeles, CA) 
following the manufacturer’s instruction.  The test in both determinations involved the 
competition of a radioactive (125I)-labeled thyroid hormone with the sample thyroid 
hormone for binding to an antibody site. After an incubation time for the reaction and the 
elimination of unbound compounds, the radioactivity of the complex (antibody-radioactive-
labeled thyroid hormone) was determined using a gamma counter.  The level of 
radioactivity, representing the amount of radioactive-labeled thyroid hormone bound to the 
antibody site was inversely proportional to the concentration of the thyroid hormones in the 
sample.  
The selenium status of the rats was determined by measuring liver glutathione 
peroxidase activity by a spectrophotometric method described by Lawrence and Burk  
(164).  The test is based on the measurement of GSH-Px activity indirectly by a coupled 
reaction with glutathione reductase.  Oxidized glutathione (GSG) produced upon reduction 
of hydroxyperoxide by GSH-Px, is recycled to its reduced form by glutathione reductase 
(GSHR) and by NADPH, which becomes oxidized to NADP+. The oxidation of NADPH 
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to NADP+ is accompanied by a decrease in absorbance at 340 nm.  The rate of decrease in 
the absorbance at 340 nm is directly proportional to GSHPx activity in the sample.  
Liver thiobarbituric acid reactive substances (TBARS), mostly composed of 
malondialdehyde (MDA) were assessed as an indicator of lipid peroxidation.  Liver MDA 
was assessed using the method described by Phelps and Harris (165) with modification 
pertaining to the preparation of the liver extract and the determination of protein 
concentrations in the liver extract.  The supernatant of liver homogenate from liver samples 
stored at -70 C was prepared in the following way: liver sample was homogenized in 
50mM phosphate buffer (PBS with 1 mM EDTA, 1 mM phenymethylsulfonylfluoride, and 
1 µM pepstain A and trypsin inhibitor at 80 mg/L buffer PH = 7.4) using a homogenizer 
with cold teflon-glass and overhead stirrer (Wheaton Science Product Cat # 903475).  The 
homogenate was centrifuged at 900 g at 4 ºC for 15 min. The supernatant was decanted, 
and recentrifuged at 12,000 g (11,400 rpm) at 4 ºC for an additional 15 min. The latter 
supernatant was aliquoted and stored at -80 ºC for TBARS analysis.  Protein concentrations 
of the liver extracts were determined by the Bio-Rad Protein Assay (Bio-Rad Laboratory, 
Hercules, CA) using bovine serum albumin (BSA, Sigma Chemical Co., St. Louis, MO) as 
the standard.   
As an indicator of antioxidant status, serum ferric reducing ability of plasma 
(FRAP) was determined.  Serum FRAP was assessed colorimetrically with a commercially 
available kit from Roche Diagnostics (Somerville, NJ) using a Cobas-Fara II Clinical 
Analyzer (Montclair, NJ).  
As indicators of biochemical markers of bone metabolism we assessed serum 
osteocalcin, serum alkaline phosphatase (ALP), serum tartrate resistant acid phosphatase 
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(TRAP), urinary deoxypyridinoline (DPD), urinary calcium, urinary magnesium, and 
urinary phosphorus. 
Serum osteocalcin was analyzed to assess bone formation using a rat osteocalcin 
immunoradiometric assay (IRMA) kit (Immunotopics, Inc, San Clemente, CA) following 
the manufacturer’s instructions.  Two different antibodies to rat osteocalcin are used in the 
assay.  An affinity purified polyclonal goat antibody recognizing the C-terminal portion of 
the molecule was immobilized onto plastic beads for capture and another affinity purified 
polyclonal goat antibody recognizing the amino terminal portion of the molecule was 
radiolabeled for detection.  A sample containing rat osteoclacin was incubated 
simultaneously with an antibody coated bead and the 125I labeled antibody.  Osteocalcin 
contained in the sample is immunologically bound by the immobilized antibody and the 
radiolabeled antibody to form a “sandwich” complex:   
Bead/Anti-Rat Osteocalcin-Rat Osteocalcin-125I Anti-Rat Osteocalcin.  At the end of the 
incubation period, the bead is washed to remove any unbound labeled antibody and other 
components.  The radioactivity bound to the beads is then measured in a gamma counter.  
The radioactivity of the antibody complex bound to the bead is directly proportional to the 
amount of rat osteocalcin in the sample. 
Serum alkaline phosphatase as a non-specific indicator of bone formation was 
assessed using a colorimetric kit from Roche Diagnostics (Somerville, NJ).  The test was 
performed on a Cobas-Fara II Clinical Analyzer (Montclair, NJ).  The Roche reagent for 
alkaline phosphatase uses 4-notophenylphosphate as the orthophosphate monoester and 2-
amino-2-methyl-1, 3-propanediol as the phosphate receptor and buffer.  The 4-
nitrophenylphosphate is colorless, but the resultant 4-nitrophenoxide ion has a strong 
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absorbance at 405 nm.  The rate of increased absorbance at 405 nm is proportional to the 
enzyme (alkaline phosphatase) activity.   
Serum TRAP was assessed as an indicator of bone resorption using a colorimetric 
kit from Roche Diagnostics System Inc (Nutley, NJ) and the Cobas-Fara II Clinical 
Analyzer (Roche, Montclair, NJ). 
Urinary DPD was analyzed as an indicator of bone resorption using the Metra DPD 
EIA kit (Quidel Corporation, San Diego, CA) following the manufacturer’s instruction and 
using a plate reader.  The assay is a competitive enzyme immunoassay in a microtiter strip-
well format using a monoclonal anti-DPD antibody coated on the strip to capture DPD.  
DPD in the sample competes with conjugated DPD-alkaline phosphatase for the antibody 
and the reaction is detected with a p-Nitrophenyl phosphate substrate using a plate reader at 
405 nm.  Metra DPD results were expressed based on urinary concentrations of creatinine.  
Urinary creatinine was assessed colorimetrically using a kit from Roche Diagnostics Inc. 
(Nutley, NJ) and the Cobas-Fara II clinical analyzer (Roche, Montclair, NJ). 
Urinary Ca, Mg, and P were determined to know the amounts of the minerals lost in 
the urine.  Urinary calcium and magnesium were assessed using flame atomic absorption 
spectrometry (Perkin Elmer, 5100PC). 
Urinary phosphorus was assessed using a colorimetric kit from Roche Diagnostics 
(Nutley, NJ) and the Cobas-Fara II clinical analyzer (Roche, Montclair, NJ).  During the 
test, phosphorus reacts in acid medium with ammonium molybdate to form a 
phosphomolybdate complex with a yellow color.  The intensity of this color, measured at 
340 nm, is proportional to the concentration of inorganic phosphorus in the sample.  
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Bone Measurement by Dual Energy X-ray Absorptiometry (DEXA) 
Femoral, tibial, and vertebral (L3-5) bone mineral area (BMA), bone mineral content 
(BMC), and bone mineral density (BMD), were assessed by dual energy X-ray 
absorptiometry (DEXA) with small animal high-resolution software (Hologic QDR4500A 
Elite, Waltham, MA).  BMC is an estimate of the amount of mineral present in the bone, 
BMA estimates the two-dimensional area occupied by bone, and BMD is equal to BMC 
divided by BMA. 
 
Bone Structure
The microarchitecture of the trabeculae of vertebra (L3), and proximal tibia were 
analyzed using microcomputed tomography (µCT).  Specimens of bone stored at -20°C
were scanned using the µCT-40 (Scanco Medical AG, Zurich, Switzerland).  The proximal 
tibia was scanned distally from the proximal growth plate.  Contours were placed on a total 
of 125 consecutive tomographic slices (16.5 µm thickness per slice) beginning at 25 slices 
from the growth plate.  Contours were also placed on 50 slices scanned from the midshaft 
region of the tibia to analyze cortical bone volume, thickness, and porosity.   
The vertebra (L3) was scanned from proximal to distal growth plate.  Contours were 
placed on a volume of interest (VOI) beginning and ending at 10 slices (165 µm per slice) 
away from the growth plate in order to include in the VOI only the secondary spongiosa 
within the two growth plates.  Bone morphometric parameters including trabecular bone 
relative volume (BV/TV), trabecular number (TbN), trabecular separation (TbSp), and 
trabecular thickness (TbTh), as well as the structural model index (SMI), connectivity 
density (ConnD) of the trabeculae, and the degree of anisotropy (DA) were obtained for L3.
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The 3-D images were also obtained for the analyzed bone specimens for visualization as 
needed. 
 
Bone Biomechanical Tests 
Bone Biomechanical Test Using 3-point Bending. The femur from the whole left 
leg that was kept at 20◦C was separated from the tibia and cleaned to perform the 3-point 
bending test.  The femur was first measured using an electronic digital cliper (Model No 
14-648-17, VWR, Friendswood, Texas) to determine its length and its midshaft location as 
well as the anterior-to-posterior and lateral-to-lateral external diameters at the midshaft 
level.  Then the femur was broken via a 3-point bending method using a texture analyzer 
(T.\ .XT2i® Texture Analyzer, Texture Technology Corp., Scarsdale, NY).  In the 3-point 
bending test, the ends of the femur were supported by two fulcra (24 mm apart from each 
other) and the force was delivered to the midshaft by a crosshead moving at a constant 
speed.  The femur was broken from the anterior to the exterior plane by applying a 
breaking force perpendicularly to the long axis of the bone with a crosshead speed of 5.0 
mm/minute.  The following parameters were obtained for the femur: the yield load (force) 
in gram, which was converted into N, ultimate load in N, and stiffness in N/mm.  Next, the 
anterior-to-posterior and the lateral-to-lateral internal diameters of the femur at the level of 
midshaft were measured as well as the thickness of the cortical bone using the same caliper 
that was used to measure the length of the bone.  Other biomechanical parameters such as 
the modulus of elasticity, yield force, ultimate force, yield stress and ultimate stress were 
calculated as described by Kiebzak and colleagues (90) and by Turner and Burr (82).  
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Briefly, the value of the second moment of area of the femur was first calculated using the 
following formula: 
 Π [(BD3) – (bd3)] 
SMA (mm4) = ________________
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Where, B is the lateral-to-lateral external diameter in mm, D the anterior-to-posterior 
external diameter in mm, b the lateral-to-lateral internal diameter in mm, and d the anterior-
to-posterior internal diameter of the femur at midshaft level in mm.  Then this value of 
SMA was used in the calculation of yield stress, ultimate stress and the modulus of 
elasticity of the femur.  The yield stress was calculated using the following formula: 
 Yield load x L x C 
Yield Stress (N/mm2) = __________________ 
 4 x SMA 
Where, L is the distance between the two fulcra that support the bone and is equal  
to 24 mm, and C is equal to half of the anterior-to-posterior external diameter. 
The ultimate stress was calculated using the following formula: 
 Ultimate load x L x C 
Ultimate Stress (N/mm2) = ______________________  
 4 x SMA 
The value of the modulus of elasticity was calculated using the following formula: 
 Stiffness x L3
Modulus of Elasticity (N/mm2) = ________________ 
 48 x SMA 
Bone Biomechanical Test Using Finite Element Analysis by Micro-CT. Finite 
element analysis uses specialized computer software and the micro-computed tomography 
(µCT) histomorphometric data to simulate compression of a region of interest of a material 
and determine the behavior of the material in response to the compression.  The third 
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lumbar vertebra, L3 was scanned from the proximal growth plate to the distal growth plate 
using µCT.  A volume of interest (VOI) composed of secondary spongiosa of L3 trabecular 
bone that was obtained for the determination of L3 microarchitecture was subjected to a 
high friction compression test in the z direction.  This allowed the determination of 
mechanical properties of the bone specimen such as average strain, total force, 
physiological force, stiffness, size independent stiffness, and average von Mises stress of 
the trabecular cores of L3
Bone Ash Weight and Mineral Content Using Atomic Absorption Spectrometry
After the 3-point bending test, the left femur was ashed to determine the amounts of 
individual minerals in it using atomic absorption spectrometry.  The concentrations of Ca, 
Mg, Zn, and Fe were determined using flame atomic absorption spectrometry (Perkin 
Elmer, 5100PC).  The femurs were weighed, dried at 105 ºC for 24 hours, re-weighed, and 
placed in individual acid-washed crucibles.  An acid digestion with concentrated nitric acid 
and hydrogen peroxide at 85 ºC was followed by a dry ashing in a muffle furnace.  Bone 
was ashed in the muffle furnace at 375 ºC for 24 hours three times with intermittent acid 
digestions and dryings until white ash was obtained (166).  After cooling, bone ash was 
weighed and dissolved in 12.2 ml of 5.2% nitric acid solution (11.6 mL water + 600 µL
concentrate nitric acid). Then appropriate dilutions of the stock solution were done for Ca, 
Mg and Zn for the analysis, while the Fe was directly assessed in the stock solution.  For 
Ca analysis the stock solution was diluted (1:2805) using 0.05% nitric acid containing 0.1% 




Data were analyzed using SAS (Statistical Analysis System) version 8 (SAS 
Institute Inc., Cary, NC).  A split plot arrangement in a completely randomized design with 
sub sampling of the subunits (pups) and considering the main units (dams) as random 
factors along with Proc Mixed and Least Square Means were used to determine the main 
and interaction effects of the independent variable (iodine, selenium and sex) on the 
dependent variables (indicators of growth, iodine status, selenium status, bone quality, and 
oxidative status of the pups).  Whenever an interaction effect was significant, slice analysis 
in Proc Mixed was used to determine the significance of differences between different 
levels of an independent variable at a given level of the other interacting independent 





EFFECTS OF IODINE AND SELENIUM STATUS ON GROWTH AND  




Iodine and selenium are essential trace elements in higher vertebrates.  The 
deficiencies of these trace elements have been implicated in the etiology of a severe type 
of osteoarthritis, called Kashin-Beck disease, occurring in children and adolescents (1), 
(2).  The mechanism by which iodine and selenium may affect bone and cartilage in 
children is not clear.  However iodine is required for the synthesis of the thyroid 
hormones, thyroxin (T4) and triiodothyronine (T3).  Thyroid hormone (T3) is necessary 
for normal bone development and maturation in infants and children and for normal bone 
and mineral metabolism in adults (3).  Untreated childhood hypothyroidism causes 
growth retardation that can be reversed by thyroid hormone replacement to produce a 
rapid catch up growth (4).  Delayed bone maturation due to iodine deficiency has been 
observed in sheep (5).  Thyroid hormones stimulate IGF-1 (insulin-like growth factor-1) 
production in humans (6), bony fish (7) and rats (8), and circulating IGF-1 regulates bone 
growth and density in mice (9).  T3 also stimulates bone mineralization and cartilage 
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matrix proteoglycan formation (10).  Low serum levels of IGF-1 and IGF binding 
protein-3 (IGFBP-3) were found in pubertal children living in an area of severe iodine 
deficiency compared to children living in an area with mild iodine deficiency (11)  
Fluvic acid, an environmental contaminant involved in the etiology of Kashin-
Beck disease, has been shown to covalently bind with iodine, indicating that fluvic acid 
may interfere with the biovavailability of iodine (12).  The mycotoxins produced by 
fungus of alternaria species, also implicated in the etiology of Kashin-Beck disease, have 
been suggested to compete for thyroid hormone (T3) receptors (13).  Thyroid hormone 
receptors are expressed in intramembranous and endochondral bone formation sites, in 
cultured osteoblasts and osteocytes, and in reserve and proliferative zones of growth plate 
chondrocytes (10).   
The mechanism of action of selenium on bone and cartilage is not clear.   
Growth retardation, osteopenia, decreased serum alkaline phosphatase, and decreased 
IGF-1 were observed in second generation selenium-deficient male rats (14).  Fluvic acid 
supplements and/or selenium deficiency impaired the structure of skeletal tissues in mice 
with characteristics similar to an early stage of osteoarthritis (15).  These animals also 
had impaired collagen structure in both bone and cartilage and lower breaking force of 
the bone. 
Selenium may protect bone and cartilage in several ways.  Selenium is required 
for the activation and the homeostasis of thyroid hormones as an essential cofactor of 
iodothyronine deiodinases (16).  Selenium as a part of antioxidant enzymes such as 
glutathione peroxidases (GSH-Pxs), thioredoxine reductases, and selenoprotein P may 
protect bone and cartilage cells against oxidative damage (17).  Several selenoproteins 
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are expressed in fetal human osteoblasts where they contribute to cell differentiation and 
defense (17).   
Iodine and selenium deficiencies have been associated with osteoarthritis, and 
osteoarthritis leads to bone loss.  Some studies have shown an inverse association 
between osteoporosis and osteoarthritis (18-19).  However, the occurrence of 
osteoporosis in osteoarthritic patients is well documented and several recent studies have 
demonstrated a positive relationship between osteoarthritis and bone loss (20-25). 
Despite this link between osteoarthritis and bone loss, there is limited information 
about the effects of iodine and/or selenium on bone density, microarchitecture, and 
biomechanical properties during growth.  There is also limited information about a 
possible gender difference in bone response to iodine and deficiency as most of the 
animal studies focused solely on male rats.  It is also not clear whether the two trace 
elements may interact to affect bone.  Because the deficiency of iodine and selenium is 
associated with osteoarthritis and arthritis is associated with bone loss, it is possible that 
Kashin-Beck disease-affected children will be at risk for bone fracture.   
We hypothesized that iodine and selenium depletion would independently reduce 
growth, impair bone metabolism, decrease bone density, deteriorate bone 
microarchitecture, and decrease bone strength in both male and female rats and that the 





Animal Experiment and Study Design
Animal Feeding and Handling. Fourteen Sprague Dawley pregnant rats (120 g to 
186 g) were ordered from Harlan Teklad, (Indianapolis, IN) and fed an adaptation diet 
(low iodine, low selenium) for the last 5 to 7 days of pregnancy and for a week of 
lactation.  Then the lactating dams were randomly assigned to four experimental diets: 
Adequate selenium, adequate iodine (+Se+I); adequate selenium low iodine (+Se-I); low 
selenium, adequate iodine (-Se+I); and low selenium, low iodine (-I -S) as indicated in 
Table I.  The experimental design is illustrated in Figure 1. Dams were fed the 
experimental diets for the last two weeks of lactation. 
Nine male and nine female pups per dietary treatment were randomly selected (for 
a total of 72) and continued on the diets of their respective mothers for  an additional 7 
weeks.  The pups were fed ad libitum with free access to reverse osmosis water.  During 
the feeding experiment, two pups (one male and one female) died in the 6th and 7th weeks 
from the group consuming the low iodine, adequate selenium diet.  The male rat died 
from an unknown cause in the 6th week and the female died under the influence of 
anesthesia at the end of the experiment during the 7th week.  Thus the total number of 
pups remaining for the experiment was 70.  The use of rats in this study was approved by 
the Institutional Animal Care and Use Committee (IACUC) of Oklahoma State 
University. 
Preparation of the Experimental Diets. The experimental diets followed the 
recommendations of the American Institute of Nutrition (AIN) for growing rodents (26), 
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(see Table I) with some modifications.  The diets were isocaloric and isonitrogenous.  
Because casein is contaminated with some selenium, torula yeast was used as a protein 
source instead of casein while correcting for the amount of carbohydrate provided by 
torula yeast.  Cornstarch was replaced with dextrose to counteract the bitterness of torula 
yeast.  Mineral and vitamin mixes were equivalent for the four different diets, except for 
iodine and selenium, which were either added or not added according to whether the diet 
was adequate or low in iodine and/or selenium.  Potassium iodate and sodium selenate 
were used as sources of iodine and selenium respectively.  The mineral mix was 
made in the Nutritional Sciences laboratory at Oklahoma State University.  The vitamin 
mix was formulated according to the recommendations of AIN (Cat # 40060, Harlan 
Teklad, Madison, WI) and kept refrigerated until diets were mixed.  The diets were 
mixed in batches of 5 kg in a mixer.  Diets were kept refrigerated and pups continued to 
be fed daily the diets of their mothers for 7 weeks after weaning, after which they were 
necropsied.  
Necropsy . The day before the necropsy, rats were fasted overnight in individual 
metabolic cages for a 12-hour urine collection.  Then the rats were anesthetized with an 
intraperitoneal injection of mixed ketamine (75mg/kg body weight)/xylazine (10mg/kg 
body weight), and weighed while they were sleeping.  Blood from the abdominal artery 
was chilled and then centrifuged for five minutes at low speed to separate serum that was 
stored at -20°C.  Urine samples were also stored at –20°C.  A portion of the liver was 
quickly collected, weighed and put in liquid nitrogen before being stored at -70°C.  
Tissues and bones were weighed and kept at -20°C.  
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Determination of Weight Gain, Organ weight, and Body Lean and Fat Mass. 
Thyroid weight was determined directly by excising and weighing the thyroid 
gland at the time of necropsy.  Organs such as liver, heart, and spleen also were excised 
and weighed.  The body lean and fat weights were assessed using DEXA.  In this 
dissertation all organ weights and the lean and fat weights are expressed as percent of 
total body weight. 
 
Biochemical Analyses:
Serum thyroxin (T4) and serum triiodothyronine (T3) were measured using radio 
immunoassay (RIA) kits (Diagnostic Products Corp., Inc, Los Angeles, CA).  Liver 
glutathione peroxidase activity was measured spectrophotometrically (27). 
Liver thiobarbituric acid reactive substances (TBARS) measured as 
malondialdehyde (MDA) were assessed as an indicator of lipid peroxidation using the 
method of Phelps and Harris (1993) with modifications.  Liver samples stored at -70 C 
were homogenized in 50 mM phosphate buffer (PBS with 1 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride, and 1 µM pepstain A and trypsin inhibitor at 80 mg/L 
buffer PH = 7.4) using a cold teflon-glass homogenizer with overhead stirrer (Wheaton 
Science Products, Cat # 903475).  The homogenate was centrifuged at 900 g at 4 ºC for 
15 min. The supernatant was decanted, and recentrifuged at 12,000 g (11,400 rpm) at 4 
ºC for an additional 15 min. The latter supernatant was aliquoted and stored at -80 ºC for 
TBARS analyses.  Protein concentrations of the liver extracts were determined by the 
Bio-Rad Protein Assay (Bio-Rad Laboratory, Hercules, CA) using bovine serum albumin 
(BSA, Sigma Chemical Co., St. Louis, MO) as the standard.   
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Serum ferric reducing ability of plasma (FRAP) was assessed colorimetrically 
with a kit from Roche Diagnostics (Somerville, NJ) using a Cobas-Fara II Clinical 
Analyzer (Montclair, NJ) as a measure of antioxidant status 
As indicators of bone metabolism we assessed serum osteocalcin, serum alkaline 
phosphatase (ALP), serum tartrate resistant acid phosphatase (TRAP), urinary 
deoxypiridinoline (DPD), urinary calcium, urinary magnesium, and urinary phosphorus. 
Serum osteocalcin was analyzed to assess bone formation using a rat osteocalcin 
immunoradiometric assay (IRMA) kit (Immunotopics, Inc, San Clemente, CA) following 
the manufacturers’ instructions.  Serum alkaline phosphatase, serum TRAP and urinary 
creatinine were assessed using colorimetric kits from Roche Diagnostics (Nutley, NJ) and 
Cobas-Fara II Clinical Analyzer (Montclair, NJ).  Urinary DPD was analyzed as an 
indicator of bone resorption using the Metra DPD EIA kit (Quidel Corporation, San 
Diego, CA).   
Urinary calcium and magnesium were determined using flame atomic absorption 
spectrometry (Perkin Elmer, 5100PC, Norwalk, CT).  Urinary phosphorus was assessed 
using a colorimetric kit from Roche Diagnostics (Nutley, NJ) and the Cobas-Fara II 
clinical analyzer (Montclair, NJ).   
 
Bone Measurement by Dual Energy X-ray Absorptiometry (DEXA) 
Femoral, tibial, and vertebral (L3-5) bone mineral area (BMA), bone mineral 
content (BMC), and bone mineral density (BMD) were assessed by dual energy X-ray 
absorptiometry (DEXA) with small animal high-resolution software (Hologic 
QDR4500A Elite, Waltham, MA). 
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Bone Structure
The microarchitecture of the trabeculae of the third lumbar vertebra (L3), and 
proximal tibia were analyzed using microcomputed tomography (µCT-40, Scanco 
Medical AG, Zurich, Switzerland).  The proximal tibia was scanned in the distal direction 
from the growth plate.  Contours were placed on a total of 125 consecutive tomographic 
slices (16.5 µm thickness per slice) beginning 25 slices from the growth plate.  
Trabecular bone volume fraction (BV/TV), trabecular number (TbN), trabecular 
thickness (TbTh), trabecular separation (TbSp), structural model index (SMI), 
connectivity density (ConnD), and degree of anisotropy (DA) were assessed.  Contours 
were also placed on 50 slices scanned at the midshaft region of the tibia to analyze 
cortical bone volume, thickness, and porosity.   
The vertebra (L3) was scanned from proximal to distal growth plate.  A countour 
was placed on a VOI beginning and ending 10 slices (165 µm) away from the growth 
plates in order to include in the VOI only the secondary spongiosa within the two growth 
plates.  Bone morphometric parameters including trabecular  BV/TV,  TbN, TbSp, and 
TbTh, as well as the SMI, ConnD and degree of anisotropy were obtained for L3.
Bone Biomechanical Tests 
Bone Biomechanical Test Using 3-point Bending. An electronic Vernier caliper 
(Model No 14-648-17, VWR, Friendswood, Texas) was used to determine femur length 
and midshaft location as well as the anterior-to-posterior, and lateral-to-lateral external 
and internal diameters at the midshaft level.  The femur was broken via a 3-point bending 
method (28) using a texture analyzer (T.\ .XT2i® Texture Analyzer, Texture Technology 
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Corp., Scarsdale, NY).  Ends of the femur were supported by two fulcra (24 mm apart) 
and the force was delivered to the midshaft by a crosshead moving at a constant speed of 
5.0 mm/minute.  The yield load (force), ultimate load and stiffness were obtained.  Other 
biomechanical parameters such as the modulus of elasticity, yield stress, and ultimate 
stress were calculated as described by Kiebzak et al. (28) and by Turner and Burr (29).   
Bone Biomechanical Test Using Finite Element Analysis by micro-CT. The µCT 
histomorphometric data were used with finite element software to simulate compression 
of a region of interest and determine the behavior of the material in response to the 
compression.  The trabecular bone sample used for the determination of L3
microarchitecture was subjected to a high friction compression test in the z direction.  
This allowed the determination of mechanical properties of the bone specimen such as 
total force for compression, average strain, stiffness and size independent stiffness, and 
von Mises stresses. 
Bone Ash Weight and Mineral Content Using Atomic Absorption Spectrometry
The concentrations of Ca, Mg, Zn, and Fe were determined using flame atomic 
absorption spectrometry (Perkin Elmer, 5100PC, Norwalk, CT).  First femurs were 
weighed, dried at 105 ºC for 24 hours and ashed using repeated acid digestions with 
concentrated nitric acid and hydrogen peroxide at 85 ºC followed by dry ashing cycles in 
a muffle furnace.  Bone ash was weighed and diluted to appropriate concentrations for 





Data were analyzed using SAS (Statistical Analysis System) version 8 (SAS 
Institute Inc., Cary, NC).  A split plot arrangement in a completely randomized design 
with sub sampling of the subunits (pups) and considering the main units (dams) as 
random factors was used along with Proc Mixed and Least Square Means (LSMEAS) to 
determine the main and interaction effects of the independent variable (iodine, selenium 
and sex) on the dependent variables (indicators of growth, iodine status, selenium status, 
bone quality, and antioxidant and lipid peroxidation status of the pups).  We used slice 
analysis in the LSMEANS statement whenever an interaction effect was significant or 




Weight Gain and Bone Density
The effects of iodine and selenium depletion on growth and indicators of iodine 
and selenium status are presented in Table II. Male rats had significantly higher weight 
gain than females for both selenium adequate (P<0.0001) and selenium deficient 
(P<0.0001) diets (Figure 2).  Weight gain was significantly reduced by iodine deficiency 
in all rats (P<0.008) (Table II) and by selenium deficiency in males (P<0.0001).  
Selenium depletion did not affect the weight gain of females rats (Figure 2).  Thyroid 
weight as a percentage of body weight was significantly increased by iodine depletion 
(P<0.0001), but not by selenium depletion.   
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Serum thyroxin (T4) was significantly decreased by iodine deficiency (P<0.0001) 
and selenium depletion tended (P<0.08) to increase T4 (Table II). For serum 
triiodothyronine (T3), there were no significant differences between males and females 
when selenium was adequate. But when selenium was deficient, females had higher 
serum T3 than males.  In males as well as in females, there were no significant differences 
between adequate selenium and deficient selenium with respect to serum T3 (Figure 2).  
Selenium depletion markedly decreased hepatic glutathione peroxidase activity 
(P<0.0001) regardless of sex and iodine status of the rats (Table II). 
The results for the analysis of tibial, femoral and vertebral BMA, BMC and BMD 
by DEXA are presented in Table III and IV. Iodine depletion independently reduced 
bone mineral area of the long bones (Table III).  Although BMA displayed similar 
patterns in response to selenium depletion in all three bones, there was a significant 
independent reduction with selenium depletion only in the tibia.  Selenium depletion 
decreased vertebral BMA in males (P<0.05) without affecting the BMA of vertebra in 
females.  Bone mineral area was higher in males than females in both selenium adequacy 
(P<0.0001) and selenium deficiency (P<0.0004) in the vertebra.  Selenium depletion 
decreased vertebral bone mineral area in males (P<0.05) without affecting the BMA of 
the vertebra for females (Figure 3).  
In male rats, selenium depletion significantly decreased femoral (P<0.05), tibial 
(P<0.02) and vertebral (P< 0.004) bone mineral BMC (P<0.02) without affecting the 
BMC in females (Figure 4).  When selenium was adequate, males had higher BMC than 
females in femur, tibia, and vertebra.  The same pattern was observed in all the three 
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bone when selenium was deficient, but a significantly higher BMC in males than females 
in selenium deficiency was seen only in tibia.  
 Vertebral bone mineral density was significantly decreased by selenium depletion 
in males (P<0.006), and selenium depletion tended to decrease tibia bone mineral density 
in males (P<0.09) (Figure 5).  Vertebral BMD was higher in males than females when Se 
was adequate (P<0.04). 
 
Bone Growth, body Lean Mass, and Fat Mass
The lengths of the tibia and femur were measured using a digital caliper.  Both 
iodine and selenium depletion significantly decreased tibia and femur lengths and males 
had longer tibia and femur than females (P<0.0001) (Table V).  Mean femur cortical 
thickness as measured by the caliper was reduced by selenium deficiency (P<0.04).   
There were no diet effects on whole body fat and lean mass as measured by 
DEXA.  Whole body lean weight was higher in female than male rats, while whole body 
fat weight was higher in males than females (P<0.04) (Table V). 
Organs (liver, spleen, and heart) were weighed at the time of necropsy.  The 
weights of all the three organs as expressed in percentage of whole body weight were 
higher in female than male rats (Table VI).  Both liver and spleen weights were 
decreased by iodine deficiency, and selenium depletion increased liver weight.  There 




The three-dimensional analysis of both proximal tibia and L3 was performed using 
micro-computed tomography (µCT).  The results for the assessment of the 
microarchitectural parameters for proximal tibia and the third lumbar vertebra (L3) are in 
Tables VII and VIII. 
Male rats had larger bone than females as evidenced by the significantly larger 
trabecular total volume (TV) in both tibia (Table VII and VIII).  Iodine and selenium 
deficiency independently reduced the total trabecular volume in the tibia.  Males had 
higher L3 trabecular TV than females in both iodine adequacy (P<0.002) and iodine 
deficiency (P<0.001) (Figure 6).  A significantly lower relative bone volume (BV/TV) 
was found in males than females in both tibia and L3 (Tables VII and VIII).  When 
iodine was adequate, the deficiency of selenium increased tibia (P<0.04) and vertebra 
(P<0.03) trabecular BV/TV, but when selenium was deficient, the adequacy of iodine 
tended to increase BV/TV in the tibia (P<0.06) (Figure 6). 
Females had also higher tibial trabecular number (P<0.0008) and higher L3
trabecular number (P<0.0001) than males (Table VII and VIII).  In a pattern similar to 
that of BV/TV, tibia and L3 TbN were increased in iodine adequate animals when 
selenium was deficient (P<0.005) and (P<0.02) respectively.  When selenium was 
adequate, the depletion of iodine increased both Tibia and L3 TbN.  But when selenium 
was deficient the adequacy of iodine significantly increased tibia TbN (P<0.02) (Figure 
7).  There were no significant differences between iodine-adequate and iodine-deficient 
rats with respect to L3 TbN when selenium was deficient.   
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Trabecular thickness (TbTh) was significantly higher in females than males for 
proximal tibia (P<0.0001) (Table VII).  In selenium depleted rats, L3 TbTh was higher in 
females than males (P<0.004), but when selenium was adequate, there were no 
significant differences between males and females in terms of L3 TbTh (Figure 8). 
The results from TbSp, ConnD, SMI, DA and BS/BV are presented in Tables IX 
and X. Tibial trabecular separation tended to be higher in males than in females (P<0.06) 
and L3 trabecular separation was significantly higher in males than females (P<0.0001).  
Both tibia and L3 trabecular separation were higher in iodine adequate animals when 
selenium was also adequate (P<0.02 and P<0.002 respectively), but when selenium was 
deficient, the adequacy of iodine decreased tibial TbSp (P<0.02) (Figure 9).  L3
trabecular separation was decreased in selenium adequate rats when iodine was deficient 
(P<0.0009) (Figure 9). 
The connectivity density (ConnD) of both proximal tibia and L3 trabecular bone 
was significantly higher in females than males (P<0.0001 and P<0.0005 respectively) 
(Tables IX and X).  When iodine was adequate, the deficiency of selenium increased the 
connectivity for both tibia and L3 (P<0.02 and P<0.01 respectively), but when selenium 
was deficient, the adequacy of iodine significantly increased ConnD in both tibia 
(P<0.04) and L3 (P<0.005) (Figure 10).   
The structural model indices (SMI) of both tibia and L3 trabecular bone were 
significantly lower in females than males which mean bone was more plate-like in 
females and more rod-like in males.  When iodine was adequate, the deficiency of 
selenium decreased L3 SMI (P<0.03) and tended to decrease tibial SMI (P<0.08).  L3 SMI 
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also tended to be decreased by selenium depletion in iodine adequate rats (P<0.07) 
(Figure 11).
The degree of anisotropy was higher in males than females in the proximal tibia 
(P<0.0001) but higher in females than males in L3 (P<0.0002).  The mean degree of 
anisotropy in the proximal tibia was higher when iodine was adequate (P<0.0001) but 
diet did not have significant effects on DA in L3 (Tables IX and X)
The ratio of bone surface to bone volume (BS/BV) was higher in males than 
females for tibia (P<0.0001), and L3 BS/BV was higher in males than females when 
selenium was depleted (P<0.0004) (Figure 12).   
Tibia Cortical Bone Microarchitecture
The 3-D analysis of 50 slices of tibial cortical bone presented in Table XI shows 
that males had higher cortical total volume (P<0.0008) and bone volume (P<0.002) than 
females when Se was adequate (P<0.0001) (Table XI).  But when selenium was 
depleted, there were no significant sex differences with respect to tibial cortical TV and 
BV (Figure 13).  Similarly, males rats had higher tibial cortical thickness than females 
when selenium was adequate (P<0.04).  Tibial cortical porosity was decreased by iodine 
depletion in male rats (P<0.003) and when iodine was adequate, males had higher tibial 
cortical porosity than females (P<0.03) (Figure 14).   
 
Biochemical Markers of Bone Metabolism
The measured bone formation markers were serum alkaline phosphatase and 
serum osteocalcin.  Iodine and selenium depletion did not significantly affect serum 
71
alkaline phosphatase.  However, the values were higher in males than females (P<0.03) 
(Table XII).  Serum osteocalcin levels were decreased by selenium depletion (P<0.04) 
and there were significantly higher values of serum osteocalcin in females than males 
(P<0.02) (Table XII).   
As bone resorption markers, we assessed serum TRAP, urinary DPD, urinary Ca, 
Mg, and P (Tables XII and XIII).  When iodine was adequate, serum TRAP was higher 
in males than females (P<0.004), but when iodine was deficient there were no significant 
differences between males and females in serum TRAP (Figure 15).   
There were no significant effects of either diet or sex on urinary DPD and urinary 
Ca.  However, urinary Mg (P<0.007), urinary P (P<0.04) (Table XIII) and urinary 
creatinine (P<0.03) (APPENDIX M) were higher in males than females.  As markers of 
oxidative status we determined liver glutathione peroxidase (GSH-Px) activity, which 
was also an index of selenium status, serum FRAP, and liver TBARS as measured by 
malondialdehyde.  Hepatic GSH-Px activity was decreased by selenium depletion 
(P<0.0001), but was not affected by iodine depletion (Table II).  Serum FRAP 
concentrations were decreased by selenium depletion (P<0.04) (Table XIII) and there 
was significantly higher serum FRAP in females than males when iodine was deficient 
(P<0.02) (Figure 15).  Serum FRAP was also increased by iodine depletion in females 
(P<0.01).  
Hepatic TBARS as expressed in MDA levels in liver extract were increased by 
selenium depletion (P<0.0001), and iodine depletion (P<0.03); and males had higher 
levels of TBARS than females (P<0.0001) (Table XIII).   
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Bone Ash Weight and Mineral Content
There were no significant effects of iodine and/or selenium on femur wet weight, 
dry weight, and ash weight.  However, femur wet weight and dry weight were both 
higher in males than females (P< 0.02), but femur ash weight as percent of either wet or 
dry weights was higher in females than males (P<0.002 and P<0.03 respectively) (Table 
XIV).   
 Femur concentrations of calcium, magnesium, zinc and iron as measured by flame 
atomic absorption spectrometry were not affected by iodine and/or sex of the animals.  
Selenium depletion increased femur Zn (P<0.01) and decreased femur Fe (P<0.05) 
without significantly affecting the bone concentrations of Ca and Mg (Table XV). 
 
Biomechanical Analyses
Femur 3-Point Bending. Results for the 3-point bending test of femur are 
presented in Table XVI. Femur yield force (the load required to cause permanent 
damage to the femur at the level of midshaft) was significantly decreased by selenium 
depletion in iodine adequate rats (P<0.009) and was also reduced by iodine depletion in 
selenium adequate rats (P<0.02) (Figure 16).  The ultimate force required to break the 
femur was decreased in iodine adequate rats when selenium was depleted (P<0.002) 
(Figure 16).  When selenium was adequate, the depletion of iodine also decreased femur 
ultimate force (P<0.0007) (Figure 16).  The stiffness of bone is defined as its rigidity 
(29).  Iodine adequacy increased femur stiffness in female rats (P<0.002) without having 
any significant effects on the bone stiffness of males (Figure 16).  When iodine was 
adequate, females had a tendency of higher femur stiffness than males (P<0.07).  Femur 
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modulus of elasticity (the intrinsic stiffness or the stiffness corrected for the size of bone) 
was higher in females than males (P<0.0006) and selenium depletion tended to increase 
the values in all the animals (P<0.06) (Table XVI). 
Yield stress and ultimate stress are the maximum amount of stress bone can 
sustain before having permanent damage and breaking respectively (29), therefore, they 
reflect the strength of bone (29).  Femur yield stress (P<0.008) and ultimate stress 
(P<0.02) were both higher in females than males.  There were no significant diet effects 
on femur yield stress and ultimate stress (Table XVI) 
L3 Finite Element Analysis (FE) by micro-CT. The results on the FE analysis of 
L3 trabecular bone by micro-CT are presented in Table XVII. The FE analysis with high 
friction compression test in the z-direction of L3 trabecular cores showed that the total 
force required to completely crush L3 trabecular cores was higher in females than males 
(P<0.0001) and females had higher average strain than males (P<0.0001).  The stiffness 
of L3 trabecular cores tended to be higher in females than males (P<0.09).  Size 
independent stiffness was higher in females than male rats (P<0.0003) (Table XVII), and 
the values were decreased in iodine adequate rats that were also selenium adequate 
(P<0.03) (Figure 17).  When selenium was adequate, the adequacy of iodine significantly 
decreased L3 size independent stiffness (P<0.04).  The corrected average von Mises stress 





Growth, expressed by weight gain was significantly reduced by iodine depletion 
in all rats and by selenium depletion in male rats.  The result of our study on weight gain 
with respect to selenium adequate and selenium deficient male groups is in agreement 
with those of Moreno-Reyes and colleagues (14) who observed a significant reduction of 
body weight in 74-day old, second-generation selenium-deficient male rats compared to 
control.  This growth impairment due to selenium deficiency may be due to an 
insufficient pituitary local deiodination of T4 to form T3, which is needed for growth 
hormone synthesis (14).  Moreno Reyes and colleagues found significantly decreased 
pituitary growth hormone and plasma IGF-I in second generation selenium-deficient male 
rats (14).  A decreased growth due to iodine and/or selenium depletion in our study has 
been confirmed by decreased weight gain and decreased bone length. 
 In our study, mean thyroid weight was significantly increased by iodine 
deficiency as we expected.  The thyroid weights and thyroxin levels in our control and 
iodine deficient males are similar to but higher than those found in our previous study 
(30) with weanling male rats fed the AIN diet for five weeks and the results found by Ruz 
et al. (31) with male rats fed the AIN diet for six weeks.  However, thyroid weight was 
not affected by selenium deficiency.  In addition, the combination of iodine and selenium 
deficiencies did not increase thyroid weight above the increase caused by iodine 
deficiency alone.  This was strange because selenium deficiency is supposed to worsen 
the effect of iodine deficiency, as Se is needed for thyroid hormone metabolism.  
However, similar results were found by Ruz and colleagues (31).   
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Serum thyroxine level was significantly decreased by iodine deficiency, but there 
were no significant differences among iodine depleted and iodine adequate rats with 
respect to serum T3. This might have been due to the considerable capacity of the body to 
conserve T3. However, we suggest that a longer feeding of the animal would lead to 
decreased T3 in iodine-deficient rats.  There was a significant decrease in thyroid T4 with 
T3 being unaffected in iodine-depleted animals.  This is consistent with results of studies 
considered by the Food and Nutrition Board (32), which indicates that iodine deficiency 
decreases serum T4 concentrations while serum T3 concentrations remain normal or 
increase.    
Female rats had higher T3 than males when selenium was deficient, probably due 
to some compensatory mechanisms in females we have yet not been able to identify.  The 
significantly lower T3 in males due to selenium depletion is consistent with a decreased 
weight gain in males due to selenium depletion.  This might have contributed to the 
poorer bone quality of males compared to female rats.  Probably, males are more 
sensitive to lack of Se necessary to produce iodothyronine deiodinases (Type I and type 
II) which are responsible for the conversion of T4 to T3 (16).  There were no significant 
differences between adequate selenium and deficient selenium male rats with respect to 
serum T3. The selenium deficient growing male rats of Moreno-Reyes and colleagues 
(14) did not experience a significant decrease in T3 levels compared to control, but there 
was a trend toward decreased T3 due to selenium depletion (P = 0.06), because they had a 
longer study period than we did. 
Vertebral BMD was significantly lower in selenium depleted males and selenium 
depletion tended to decrease tibial bone mineral density.  However, there were no 
76
significant sex, diet or interaction effects on femoral bone mineral density.  This was 
expected because the bone remodeling process is more active in the vertebra than the 
peripheral bones (33), and vertebra has more chancellors bone and, thus is more prone to 
bone loss than the tibia and femur.   
Bone mineral area was significantly decreased by iodine depletion in femur and 
tibia of all animals with higher BMA in males than females.  Selenium depletion also 
decreased BMA in the tibia of all the animals, in the vertebra of male rats and had a slight 
tendency (P=0.08) to decrease bone mineral area in the femur of male rats.  This suggests 
that selenium may have more effects on the bone area of males than female rats.   
Vertebral, tibial, and femoral bone mineral contents were all decreased by 
selenium depletion in male rats without any significant effects on the bone mineral 
content of female rats.  This further confirms a possible greater demand of selenium for 
male rats than female rats, even though there were no sex effects on liver GSH-Px 
activity in our study.  There are many other selenoproteins we did not assess including 
perm flagella seleoprotein, which is required for sperm motility and is suggested to play 
an important role in male fertility (34).  Many other selenoproteins have been identified 
whose role have not been characterized.   
The µCT analysis of trabecular bone structure showed that trabecular total volume 
was independently decreased by iodine and selenium depletion, and males had higher 
trabecular total volume in the tibia.  This indicates that males had larger bones.  Despite 
this larger bone in males, other microarchitectural parameters of trabecular bone such as 
TbN and TbTh were higher in females than males and TbSp was higher in the bone of 
males than females.  In humans, trabecular number and thickness decrease in aging with 
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increased trabecular separation. (35).  Since aging is associated with higher prevalence of 
bone disorders, it is probable that the bone quality of male growing rats is less than that 
of female growing rats in terms of microarchitecture. 
The structural model index (SMI) of both L3 and tibia trabeculae was significantly 
lower in females meaning that the structure of the bone for females was more plate-like.  
The SMI characterizes a 3-D bone structure composed of certain amounts of plates and 
rods (33).  Ding and colleagues (33) as well as Lane et al. (36) define SMI as a value 
between 0 and 3, and suggested that the SMI value would be 0 in an ideal plate structure 
model, and 3 in an ideal cylindrical rod structure, independent of the physical dimensions 
of the structure.  The authors suggest that human tibia cancellous bone changes with age 
from plate-like to rod-like.  Negative values of SMI have been reported and are suggested 
to occur in very dense bones.  In our study, most of the SMI values were within the range 
of 0 to 3, but some negative values were observed in five female rats fed adequate iodine, 
low selenium diet, and this contributed to the relatively lower mean SMI in this group of 
rats.  In our study female rats had significantly lower L3 SMI (more plate-like) than male 
rats indicating that female rats had better L3 cancellous bone structure.   
Cancellous bone connectivity density was higher in female than males.  In 
contrast to the study of (37) who found an inverse relation between connectivity density 
and stiffness, both connectivity and stiffness were higher in female rats and we consider 
our female rats to have a better bone quality.  Therefore, connectivity may be positively 
associated with elastic properties of the bone in growing rats.   
 Tibial cortical bone structure was also affected by sex and diet.  Tibia cortical 
thickness as measured by micro-CT was higher in selenium adequate males that were also 
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iodine adequate. But this positive characteristic was offset by a concomitant increase in 
tibial cortical porosity in iodine adequate male rats, meaning that bigger bone size due to 
more rapid growth may deteriorate cortical bone structure.  This is in part supported by 
high cortical bone volume and total volume in selenium adequate and iodine adequate 
males.  The higher cortical porosity in iodine adequate male rats may be explained by the 
higher serum TRAP observed in these animals as compared to iodine adequate females. 
Our data indicate that there is a significantly higher bone turnover in male than 
female rats.  This was evidenced by higher serum ALP and TRAP activities in males than 
females.  In addition, there were higher urinary excretions of P and Mg in males than 
females.  Serum osteocalcin was higher in females and was decreased by selenium 
depletion.  We do not know the mechanism by which selenium depletion may decrease 
serum osteocalcin levels.  Moreno-Reyes and colleagues (14) also found decreased serum 
osteocalcin in selenium deficient male rats.  There are 18 different selenoproteins 
identified in the mammalian system (34), and the functions of many of them have not yet 
been identified.  The mechanism whereby selenium may affect serum osteocalcin levels 
and the reason for higher serum osteocalcin in females are not known and further 
investigation in this area is needed.   
It has been suggested that estrogen increases the rate of bone mineralization in 
female rats at puberty compared to male rats (38).  The mechanism of this high 
mineralization of female bone at this time of high circulating estrogen levels is not 
known.  Because females had higher osteocalcin in this study and better bone status, it 
would be interesting to investigate whether this action of estrogen is mediated by 
osteocalcin. 
79
An increase in liver MDA and a decrease in serum FRAP due to selenium-
depletion may indicate a higher propensity of lipid peroxidation in selenium-deficient 
rats.  MDA is a secondary product of lipid peroxidation, and its levels have been shown 
to be high in plasma of patients with rheumatoid arthritis including children with juvenile 
rheumatoid arthritis (39).  The TBARS values obtained for our control rats are similar to 
the values found in seven-week old male (control) rats by Poon et al. (40) using a 
fluorescence method.  Liver MDA was higher and serum FRAP was lower in males than 
females.  Lipid peroxidation might have contributed to the poorer bone quality observed 
in male rats as male rats also had higher body fat and lower lean mass.  Glutathione 
peroxidase activity and other selenoproteins with antioxidant properties such as 
thioredoxin reductases and selenoprotein P might have contributed to the value of serum 
FRAP in selenium adequate rats.   
Iodine depletion also decreased liver TBARS.  The best known role of iodine in 
the body is for the synthesis of thyroid hormone.  However, substantial amounts of the 
body’s iodine are non-hormonal and are concentrated in extrathyroidal tissues where their 
physiological functions are unknown.  Iodine is rich in electrons and can act as an 
electron donor to hydrogen peroxide and peroxides.  It can also bind to the double bonds 
of polyunsaturated fatty acids of cell membranes making them less sensitive to oxidation.  
Therefore iodine is believed to have antioxidant properties in tissues where it 
accumulates (41).  For instance, the mammary gland concentrates iodine during 
pregnancy and lactation, and this concentration is suggested to prevent breast cancer (42).  
This probable antioxidant property of iodine might have contributed to the decreased 
liver TBARS values observed in iodine adequate rats. 
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Female rats had also higher femur ash weight than males.  There were no 
significant sex effects on femur bone mineral content as measured by atomic absorption 
spectrometry.  Because there was a higher femur ash weight in females than males, it is 
possible that some of the minerals we did not assess in the femur are higher in females.  
Inorganic phosphates are important components of bone and femur phosphorus 
concentration was not assessed in this study.  Because urinary phosphorus excretion was 
higher in males than females, it would be interesting to assess the phosphorus 
concentrations of femur bone solution. 
 In this study, the fastest growing animals (iodine adequate rats and selenium 
adequate male rats) had the highest femoral breaking force (ultimate force).  This may be 
due to their bigger bone size leading to a larger breaking cross-sectional area of the long 
bone.  In addition, the higher cortical TV, BV, and thickness in selenium adequate males 
might have contributed to the higher breaking force.  This bigger bone size in some male 
rats and other fast-growing rats might have also contributed to the relatively better bone 
quality with respect to bone area; mineral content and density by DEXA in comparison to 
bone microarchitecture, as DEXA analysis combines both cortical and cancellous bone. 
The relatively better bone quality in single element-depleted or both iodine and 
selenium depleted rats compared to control rats and in female rats compared to males 
may be explained by their relatively slow growth rate.  Normal growth requires a 
balanced bone reaorption and formation.  Antiresorptive agents administrated to growing 
rats impair growth and lead to increased bone mass (43).  This indicates that bone 
resorption is an important part of growth process.  In addition, T3 and estrogen might 
have had a synergistic or additive effects on females in slowing longitudinal growth by 
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inducing hypertrophy of the chondrocytes and accelerating the closure of the epiphyseal 
growth plate, which ends longitudinal growth in humans (10).  Even though T3 is 
believed to induce the differentiation of reserve chondrocytes to proliferative zone 
chondrocytes either directly (10, 44) or indirectly through GH and IGF-1 (4), its role in 
inducing hypertrophy in the chondrocytes to stop the clonal expansion of the cells is well 
recognized (10).  We did not assess the estrogen levels of the rats.  However, other 
research indicate that females have higher circulating estrogen than males at puberty (45) 
and our rats had reached the state of puberty by the time they were sacrificed.  Estrogen 
(17 β-estradiol) supplementation of both males and females growing rats caused 
decreased body weight gain, tibial length, and width of growth plate, while the opposite 
effects were caused in overiectomized rats (46).  This tempering effect of growth by 
estrogen was explained by a decrease in the width of hypertrophic zone of the growth 
plate chondrocytes and a predominant expression of estrogen receptor α and β in late 
proliferating and early hypertrophic chondrocytes in estrogen-supplemented rats. 
Because iodine and selenium deficiencies have been associated with 
osteoarthritis, we assumed that iodine and/or selenium depletion would cause 
osteoarthritis and that osteoarthritis would lead to decreased bone quality in growing rats. 
Yet we did not assess any indices of osteoarthritis.  This is an important limitation of this 
study because it makes it difficult to link our results with Kashin-Beck disease.  
However, some observations in our study are consistent with the characteristics of Kahin-
Beck disease.  The significant reduction of growth experienced by iodine and/or 
selenium-depleted animals in our study is a feature of Kashin-Beck disease (1) and we 
found a concomitant reduced growth and bone density in selenium depleted male rats.  In 
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addition, Kashin-Beck disease has been suggested to result from oxidative damage (47) 
and we observed a significant reduction of circulating antioxidant in selenium deficient 
rats and a significant increase in lipid peroxidation in the liver of I and selenium depleted 
rats.  Based on these observations, we suggest that iodine and selenium depletion studies 




These results indicate that the degree of iodine and selenium depletion used in this 
study impaired iodine and selenium status in the animals, and this might have contributed 
to following observed effects on growth and bone quality of the growing rats.  There was 
a substantial natural sex differences among the rats and iodine and selenium differentially 
affected the bone of males and female rats.  Adequacy of both iodine and selenium 
caused a rapid growth with relatively impaired bone quality as measured by trabecular 
bone microarchitecture and stiffness.  The combined deficiency of the two trace elements 
reduced growth and bone quality as measured by trabecular number and connectivity that 
could be improved by the adequacy of either iodine or selenium.  Female rats had slower 
growth rate, better oxidative status and better biomarkers of bone turnover, higher bone 
ash weight, and higher bone strength.  Mechanisms whereby iodine and selenium 
depletion affects bone quality require further investigations. 
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Adaptation Diet (-Se-I) Last 5-7 days 
 14 Sprague Dawley pregnant rats                          of pregnancy  
 & 7 days of 
 lactation 
 
14 days of  
 lactation 
 




M = Male, F = Female 
 














9 M 9 F 9 M 9 F 9 M 9 F 9 F9 M
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Table I 
Composition of the experimental diets (g/kg diet) 
 






Mineral mix +I+Se 
Mineral mix +I-Se 
Mineral mix -I +Se 
Mineral mix -I-Se 



















































I = Iodine.  Se = Selenium. (+I+Se) = Adequate iodine, adequate selenium.  (+I-Se) = Adequate iodine, low 




Effects of sex and diet on weight gain, thyroid weight, serum thyroxin, serum 

















Sex      
Males 191 ± 4 33 ± 3 2.2 ± 0.2 54.0 ± 2.3 8.22 ± 0.57 
Females 134 ± 4 39 ± 3 2.4 ± 0.2 67.1 ± 2.2 7.43 ± 0.57 
Diet      
+Se 175 ± 4 36 ± 3 2.0 ± 0.2 61.0 ± 2.60 14.20 ± 0.58 
-Se 151 ± 4 37 ± 3 2.5 ± 0.2 60.0 ± 2.5 1.45 ± 0.56 
 
+I 172 ± 4 7 ±3 3.9 ± 0.2 62.0 ± 2.60 7.79 ± 0.56 











I <0.008 <0.0001 <0.0001 0.45 0.93 
Se <0.002 0.80 <0.08 0.78 <0.0001 
I*Se 0.43 0.91 0.18 0.30 0.49 
Sex <0.0001 0.15 0.53 <0.0001 0.33 
I*Sex 0.87 0.30 0.18 0.11 0.76 
Se*sex <0.004 0.47 0.54 <0.05 0.56 
I*Se*Sex 0.99 0.40 0.96 0.85 0.71 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium. 
–Se = Low selenium.  +I =  Adequate iodine.  -I = Low iodine.  BW = Body weight.  T4 = Thyroxin.   
T3 =Triiodothyronine.  GSHPx = Glutathione peroxidase. 
86
Figure 2: Interaction effects of selenium and sex on weight gain and serum 








Males                            Females
Diets
With +Se: Male > Female (P<0.0001)
With -Se: Male > Female (P<0.0001)
In Males: +Se > -Se (P<0.0001)















Males                             Females
Diets
With -Se: Male < Female (P<0.0001)
With +Se: Male < Female (P<0.07)
In Males: +Se vs. -Se (ns)









Effects of sex and diet on whole femur and whole tibia bone mineral area, bone mineral content, and bone mineral density by dual














Males 1.58 ± 0.02 0.35 ± 0.01 0.222 ± 0.002 1.31 ± 0.02 0.217 ± 0.005 0.165 ± 0.002
Females 1.42 ± 0.02 0.32 ± 0.01 0.225 ± 0.002 1.15 ± 0.02 0.189 ± 0.005 0.164 ± 0.002
Diet
+Se 1.53 ± 0.03 0.34 ± 0.01 0.224 ± 0.003 1.27 ± 0.02 0.211 ± 0.006 0.166 ± 0.002
-Se 1.47 ± 0.03 0.33 ± 0.01 0.221 ± 0.003 1.19 ± 0.02 0.195 ± 0.008 0.163 ± 0.002
+I 1.55 ± 0.03 0.35 ± 0.01 0.225 ± 0.002 1.27 ± 0.02 0.212 ± 0.006 0.166 ± 0.002
-I 1.45 ± 0.03 0.32 ± 0.01 0.220 ± 0.002 1.18 ± 0.02 0.19 4± 0.005 0.163 ± 0.002
Source of
variation P-values P-values P-values P-values P-values P-values
I <0.04 <0.06 0.19 <0.02 <0.06 0.42
Se 0.15 0.18 0.45 <0.04 <0.08 0.41
I*Se 0.57 0.53 0.68 0.37 0.44 0.77
Sex <0.0001 <0.0006 0.59 <0.0001 <0.0001 0.65
I*Sex 0.12 0.30 0.82 0.74 0.67 0.65
Se*sex 0.08 <0.05 0.24 0.12 <0.03 <0.07
I*Se*Sex 0.85 0.97 0.84 0.20 0.39 0.95
Values are least square means ± SEM. Effect is significant at P<0.05. +Se = Adequate selenium. –Se = Low selenium. +I = Adequate iodine. -I = Low iodine.
BMA = Bone mineral area. BMC = Bone mineral content. BMD = Bone mineral density.
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Males                        Females
Diets
With +Se: Male >Female (P<0.0001)
With -Se: Male > Female (P<0.0004)I
In males: +Se > -Se (P<0.05)











Figure 4: Interaction effects of selenium and sex on femoral, tibial, and vertebral bone 







Males                               Females
Diets
In Males: +Se > -Se (P<0.05)
In Females: +Se vs. -Se (ns)
With +Se: Male > Female (P<0.0005)














Males                           Females
Diets
In Males: +Se  > -Se (P<0.02)
In Females: +Se vs. -Se (ns)
With +Se: Male > Female (P<0.0001)













Males                         Females
Diets
In Males: +Se > -Se (P<0.004)
In Females: +Se vs. -Se (ns)
With +Se: Male > Female (P<0.0001)










Effects of sex and diet on vertebral (L3-5) bone mineral area, bone mineral content, and 
bone mineral density by dual energy x-ray absorptiometry (DEXA)  
 
Vertebral BMA (cm2 ) Vertebral BMC (g) Vertebral BMD (g/cm2 )
Gender    
Males 1.44 ± 0.02 0.325 ± 0.007 0.226 ± 0.003 
 Females 1.29 ± 0.02 0.287 ± 0.007 0.223 ± 0.003 
Diet    
+Se 1.38 ± 0.03 0.317 ± 0.008 0.229 ± 0.003 
-Se 1.34 ± 0.03 0.294 ± 0.008 0.219 ± 0.003 
 
+I 1.39 ± 0.03 0.317 ± 0.009 0.228 ± 0.003 







I 0.12 0.08 0.14
Se 0.28 0.08 <0.07 
I*Se 0.46 0.67 0.76 
Sex <0.0001 <0.0001 0.38 
I*Sex 0.67 0.91 0.47 
Se*Sex <0.02 <0.002 <0.03 
I*Se*Sex 0.94 0.99 0.90 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium.   
–Se = Low selenium.  +I = Adequate iodine.  -I = Low iodine.  BMA = Bone mineral area.   
BMC = Bone mineral content.  BMD = Bone mineral density. 
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Figure 5: Interaction effects of selenium and sex on tibial and vertebral (L3-5) bone 







Males                          Females
Diets
In Males: +Se > -Se (P<0.006)
In Females: +Se vs. -Se (ns)
With +Se: Male > Female (P<0.04)

















Males                      Females
Diets
In Males: +Se > -Se (P<0.09)
In Females: +Se vs. -Se (ns)
With +Se: Male vs. Female (ns)











Effects of sex and diet on tibial and femoral length, femur cortical thickness, and 





















Sex      
Males 37.40 ± 0.23 32.88 ± 0.19 0.66 ± 0.02 91.9 ± 0.3 8.1 ± 0.3 
 Females 35.80 ± 0.23 31.14 ± 0.19 0.68 ± 0.02 92.6 ± 0.3 7.4 ± 0.3 
Diet      
 +Se 37.09 ± 0.26 32.46 ± 0.23 0.71 ± 0.03 92.3 ± 0.3 7.7 ± 0.3 
 -Se 36.12 ± 0.25 31.57 ± 0.23 0.63± 0.03 92.2 ± 0.3 7.8 ± 0.3 
 
+I 37.37 ± 0.26 32.77 ±0.24 0.70 ± 0.03 92.0 ± 0.3 8.0 ± 0.3 







P-values P-values P-values 
I <0.002 <0.002 0.11 0.27 0.27 
Se <0.03 <0.03 <0.04 0.80 0.80 
I*Se 0.49 0.12 0.41 0.36 0.36 
Sex <0.0001 <0.0001 0.69 <0.04 <0.04 
I*Sex 0.16 0.43 0.97 0.71 0.71 
Se*sex 0.09 0.42 0.92 0.47 0.47 
I*Se*Sex 0.18 0.43 0.49 0.07 0.07 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium. -Se = 




Effects of sex and diet on organ weight 
 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium. -Se = 








Sex    
Males 3.20 ± 0.05 0.235 ± 0.004 0.39 ± 0.01 
 Females 3.48 ± 0.05 0.283 ± 0.004 0.47 ± 0.01 
Diet    
+Se 3.23  ±  0.05 0.264 ± 0.004 0.43 ± 0.01 
-Se 3.45  ± 0.05 0.254 ± 0.004 0.43 ± 0.01 
 
+I 3.43 ± 0.05 0.270 ± 0.004 0.43 ± 0.01 







I <0.02 <0.004 0.64 
Se <0.005 0.10 0.66 
I*Se <0.06 0.41 0.52 
Sex <0.0004 <0.0001 <0.0006 
I*Sex 0.97 0.99 0.58 
Se*sex 0.63 0.84 0.57 
I*Se*Sex 0.54 0.71 0.83 
Table VII













Males 24.27 ± 0.41 2.48 ± 0.12 0.102 ± 0.005 3.35 ± 0.10 0.053 ± 0.001
Females 18.47 ± 0.41 2.64 ± 0.12 0.143 ± 0.005 3.79 ± 0.10 0.058 ± 0.001
Diet
+Se 22.35 ± 0.45 2.56 ± 0.14 0.118 ± 0.006 3.43 ± 0.11 0.055 ± 0.001
-Se 20.38 ± 0.44 2.56 ± 0.14 0.127 ± 0.006 3.71 ± 0.11 0.055 ± 0.001
+I 22.85 ± 0.45 2.75 ± 0.15 0.124 ± 0.006 3.59 ± 0.11 0.055 ± 0.001
-I 19.88 ± 0.44 2.37 ± 0.14 0.121 ± 0.006 3.55 ± 0.11 0.055 ± 0.001
Source of
variation P-values P-values P-values P-values P-values
I <0.002 0.10 0.79 0.78 0.61
Se <0.02 0.98 0.34 0.11 0.72
I*Se 0.35 <0.06 <0.03 <0.004 0.56
Sex <0.0001 0.19 <0.0001 <0.0008 <0.0001
I*Sex 0.50 0.67 0.63 0.30 0.35
Se*sex 0.15 0.11 0.23 0.37 0.16
I*Se*Sex 0.46 0.73 0.83 0.70 0.71
Values are least square means ± SEM. Effect is significant at P<0.05. +Se = Adequate selenium. -S = Low selenium. +I = Adequate iodine. -I = Low iodine. TV =
Total volume. BV= Bone volume. BV/TV = Bone volume fraction. TbN = Trabecular number. TbTh = Trabecular thickness.
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Table VIII












Males 11.56 ± 0.30 2.30 ± 0.10 0.197 ± 0.005 3.30 ± 0.03 0.069 ± 0.001
Females 9.90 ± 0.30 2.41 ± 0.10 0.244 ± 0.005 3.70 ± 0.03 0.071 ± 0.001
Diet
+Se 11.23 ± 0.36 2.41 ± 0.12 0.216 ± 0.006 3.47 ± 0.03 0.070 ± 0.001
-Se 10.24 ± 0.35 2.30 ± 0.11 0.225 ± 0.006 3.52 ± 0.03 0.070 ± 0.001
+I 11.27 ± 0.36 2.44 ± 0.12 0.219 ± 0.006 3.47 ± 0.03 0.070 ± 0.001
-I 10.20 ± 0.34 2.26 ± 0.11 0.222 ± 0.006 3.53 ± 0.03 0.070 ± 0.001
Source of
variation P-values P-values P-values P-values P-values
I <0.07 0.30 0.77 0.27 0.79
Se 0.09 0.52 0.27 0.33 0.92
I*Se 0.46 0.43 <0.03 <0.006 0.54
Sex <0.0001 0.37 <0.0001 <0.0001 <0.04
I*Sex 0.81 0.54 0.77 0.19 0.82
Se*sex 0.10 <0.07 0.08 0.29 <0.02
I*Se*Sex <0.03 0.12 0.97 0.87 0.69
Values are least square means ± SEM. Effect is significant at P<0.05. L3 = Third lumbar vertebra. +Se = Adequate selenium. -Se = Low selenium. +I = Adequate iodine. -I = Low iodine. TV = Total tissue




Figure 6: Interaction effects of iodine, seleniume, and sex on third lumbar vertebra (L3)
trabecular total volume and interaction effects of iodine and selenium on proximal tibial 






+I                                 -I
Diets
With +I: +Se < -Se (P<0.04)
With -I: +Se > -Se (P<0.06)
With -Se: +I > -I (P<0.06)













+I                                 -I
Diets
With +I: +Se < -Se (P<0.03)
 with -I: +Se vs. -Se (ns)
With +Se: +I < -I  (<0.07)











Males                      Females
Diets
With +I: Male > Female (P<0.002)
With -I: Male > Female (P<0.001)
In Females: +I > -I (P<0.08)
In Males: +I vs -I (ns)
With +Se: +I > -I (P<0.08)












Figure 7: Interaction effects of iodine and selenium on proximal tibia and third lumbar 








+I                                   -I
Diets
With +I: +Se < -Se (P<0.02)
With -I: +Se vs. -Se (ns)
With +Se: +I < -I (P<0.01)










+I                                  -I
Diets
With +I: +Se  < -Se (P<0.005)
With -I: +Se vs. -Se (ns)
 With +Se: +I < -I (P<0.03)











Effects of sex and diet on proximal tibia trabecular separation, connectivity density, 








Tibia DA Tibia BS/BV 
1/mm 
Gender      
Males 0.31 ± 0.01 48.74 ± 3.76 2.59 ± 0.04 2.33 ± 0.03     51.54 ± 0.68 
 Females 0.27 ± 0.01 78.32 ± 3.76 2.27 ± 0.04 2.14 ± 0.03 45.55 ± 0.68 
Diet      
+Se 0.30 ± 0.01 59.00 ± 4.39 2.46 ± 0.05 2.27 ± 0.03 48.42 ± 0.77 
-Se 0.28 ± 0.01 68.06 ± 4.23 2.39 ± 0.05 2.20 ± 0.03 48.67 ± 0.74 
 
+I 0.29 ± 0.01 64.13 ± 4.38 2.41 ± 0.05 2.35 ± 0.03 48.94 ± 0.77 










I 0.69 0.85 0.59  <0.0001 0.87 
Se 0.32 0.17 0.34 <0.09 0.82 
I*Se <0.006 <0.01 <0.08 0.23 0.25 
Sex <0.06 <0.0001 <0.0001 <0.0001 <0.0001 
I*Sex 0.48 0.91 0.80 0.44 0.78 
Se*sex 0.68 0.39 0.70 0.39 0.23 
I*Se*Sex 0.75 0.46 0.99 0.93 0.99 
Values are least square means ± SEM. Effect is significant at P<0.05.  +SI = Adequate selenium.   
-Se = Low selenium. +I = Adequate iodine.  -I = Low iodine.  TbSp = Trabecular separation.   





Effects of sex and diet on L3 trabecular separation, connectivity density structural model 










Sex      
Males 0.301 ± 0.003 69.04 ± 1.63 1.12 ± 0.06 1.81 ± 0.02 34.40 ± 0.44
Females 0.264 ± 0.003 79.23 ± 1.63 0.48 ± 0.06 1.91 ± 0.02 32.03 ± 0.44
Diet      
+Se 0.284 ± 0.003 72.89 ± 1.65 0.93 ± 0.06 1.87 ± 0.02 33.36 ± 0.52
-Se 0.280 ± 0.003 75.39 ± 1.62 0.81 ± 0.05 1.85 ± 0.02 33.07 ± 0.52
+I 0.285 ± 0.003 75.75 ± 1.65 0.82 ± 0.07 1.87 ± 0.02 33.32 ± 0.54







P-values P-values P-values P-values 
I 0.16 0.18 0.68 0.49 0.78
Se 0.37 0.30 0.18 0.39 0.70 
I*Se <0.0006 <0.005 <0.02 0.67 0.18 
Sex <0.0001 <0.0005 <0.0001 <0.0002 <0.0006 
I*Sex 0.11 0.22 0.85 0.71 0.74 
Se*sex 0.47 0.99 0.18 0.70 <0.03 
I*Se*Sex 0.74 0.31 0.14 0.07 0.93 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium.   
-Se= = Low selenium.  +I = Adequate iodine.  -I = Low iodine.  SMI = Structural model index.  ConnD = 
Connectivity density.  DA = Degree of anisotropy.  Bs = Bone surface.  BV = Bone volume.  
100 
 
Figure 8: Interaction effects of selenium and sex on third lumbar vertebra (L3) trabecular 
thickness (TbTh) 
 
Figure 9: Interaction effects of iodine and selenium on trabecular separation (TbSp) of 





+I                                     -I
Diets
With +I: +Se > -Se (P<0.02)
With -I: +Se vs. -Se (ns)
With +Se: +I > -I (P = 0.05)













+I                                      -I
Diets
With +I: +Se > -Se (P<0.002)
With -I: +Se < -Se (P<0.06)
With +Se: +I > -I (P<0.0009)















Males                       Females
Diets
With -Se: Male < Female (P<0.004)
With +Se: Male vs. Female (ns)
In Males: +Se vs. -Se (ns)








Figure 10: Interaction effects of iodine and selenium on connectivity density of proximal 
tibia and third lumbar vertebra (L3) trabecular bone 
 
Figure 11: Interaction effects of iodine and selenium on structural model index (SMI) of 






+I                                   -I
Diets
With +I: +Se < -Se (P<0.02)
With -I: +Se vs. -Se (ns)
With +Se: +I < -I (P<0.06)


















+I                                    -I
Diets
With +I: +Se > -Se (P<0.01)
With -I: +Se vs. -Se (ns)
With +Se: +I vs. -I (ns)













+I                              -I
Diets
With +I: +Se > -Se (P<0.08)
With -I: +Se vs. -Se (ns)
With +Se: +I vs. -I (ns)











+I                                  -I
Diets
With +I: +Se > -Se  P<0.03
With -I:  +Se vs. -Se (ns)
With +Se: +I > -I  P< 0.07






Figure 12: Interaction effects of selenium and sex on third lumbar vertebra  







Males                         Females
Diets
With -Se: Male > Female (P<0.0004)
With +Se: Male vs. Female (ns)
In Males: +Se vs -Se (ns)











Effects of sex and diet on tibial midshaft cortical total volume, bone volume, 
thickness, and porosity 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium.  –Se = low 
selenium.  +I = Adequate iodine.  –I = Low iodine.  TV = Total volume.  BV = bone volume.   















Sex     
Males 2.49 ± 0.04 2.41 ± 0.04 0.491 ± 0.006 3.02 ± 0.11 
 Females 2.26 ± 0.04 2.20 ± 0.04 0.482 ± 0.006 2.90 ± 0.11 
Diet     
+Se 2.41 ± 0.05 2.33 ± 0.05 0.485 ± 0.006 3.02 ± 0.12 
-Se 2.35 ± 0.05 2.28 ± 0.04 0.488 ± 0.006 2.90 ± 0.11 
 
+I 2.43 ± 0.05 2.35 ± 0.05 0.478 ± 0.006 3.16 ± 0.11 









I 0.15 0.19 <0.06 <0.04 
Se 0.40 0.43 0.73 0.44 
I*Se 0.11 0.12 0.24 0.46 
Sex <0.002 <0.002 0.31 0.43 
I*Sex 0.99 0.87 0.82 <0.03 
Se*sex <0.06 <0.07 <0.04 0.87 
I*Se*Sex 0.50 0.56 0.08 0.13 
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Figure 13: Interaction effects of selenium and sex on tibia midshaft cortical total volume 
(TV) and bone volume (BV)  
 
Figure 14: Interaction effects of selenium and sex on tibia midshaft cortical thickness and 








Males                            Females
Diets
With +Se: Male > Female P<0.04
With -Se: Male vs.  Female (ns)
In males: +Se vs. -Se (ns)


















Males                             Females
Diets
In Males: +I > -I (P<0.003)
In Females: +I vs. -I (ns)
With +I: Male > Female (P<0.03)




















Males                          Females
Diets
With +Se: Male > Female (P<0.0008)
With -Se: Male vs. Female (ns)
In Males: +Se vs. -Se (ns)


















Males                         Females
Diets
With +Se: Male > Female (P<0.002)
With -Se: Male vs. Female (ns)
In Males: +Se vs. -Se (ns)














Effects of sex and diet on serum alkaline phosphatase, osteocalcin, tartrate resistant acid 











Sex     
Males 91.3 ± 7.3 31.3 ± 2.8 6.62 ± 0.37 168.0 ± 40.4 
 Females 71.8 ± 7.3 37.2 ± 2.8 5.86 ± 0.37 246.9 ± 40.9 
Diet     
 +Se 86.1 ± 9.2 41.0 ± 3.8 6.39 ± 0.47 198.0 ± 42.2 
 -Se 76.9 ± 9.0 27.5 ± 3.7  6.10 ± 0.46 216.9 ± 39.0 
 
+I 88.6 ± 9.6 30.7 ± 4.0 6.38 ± 0.48 231.4 ± 39.6 






P-values P-values P-values 
I 0.30 0.21 0.69 0.41 
Se 0.49 <0.04 0.67 0.74 
I*Se 0.31 0.17 0.82 0.82 
Sex <0.03 <0.02 <0.04 0.18 
I*Sex 0.27 0.21 <0.06 0.70 
Se*sex 0.32 0.96 0.46 0.13 
I*Se*Sex 0.21 0.23 0.59 0.49 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium.  -Se = Low 
selenium.  +I = adequate iodine.  –I= Low Iodine.  ALP = Alkaline phosphatase.  TRAP = Tartrate resistant 




Figure 15: Interaction effect of iodine and sex on serum tartrate resistant acid phosphatase 







Males                         Females
Diets
With +I: Male > Female (P<0.004)
With -I: Male vs. Female (ns)`
In Males: +I vs. -I (ns)
















Males                         Females
Diets
In Females: +I < -I (P<0.01)
In Males: +I vs. -I (ns)
With -I: Male < Female (P<0.02)













Effects of sex and diet on urinary Ca, urinary Mg, urinary P, serum FRAP and Liver 
thiobarbituric acid reactive substances 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium.  
–Se = Low selenium.  +I = Adequate iodine.  -I = low iodine.  Ca = Calcium.  Mg = Magnesium.  




















Sex      
Males 0.85 ± 0.41 2.64 ± 0.21 7.74 ± 0.63 528.4 ± 53.5 0.291 ± 0.003 
 Females 1.25 ± 0.42 1.89 ± 0.21 5.82 ± 0.64 714.1 ± 53.6 0.267 ± 0.003 
Diet      
+Se 1.28 ± 0.43 2.46 ± 0.24 7.52 ± 0.66 730.6 ± 61.0 0.267 ± 0.003 
-Se 0.82 ± 0.41 2.07 ± 0.23 6.04 ± 0.61 511.9 ± 59.8 0.290 ± 0.003 
 
+I 1.31 ± 0.43 2.59 ± 0.24 7.54 ± 0.62 550.6 ± 63.3 0.273 ± 0.003 




P-values P-values P-values 
 
P-values P-values 
I 0.40 0.09 0.09 0.13 <0.03 
Se 0.46 0.28 0.11 <0.04 <0.0001 
I*Se 0.40 0.27 <0.07 0.18 0.20 
Sex 0.51 <0.007 <0.04 <0.02 <0.0001 
I*Sex 0.29 0.35 0.78 <0.03 0.20 
Se*sex 0.30 0.18 0.43 0.55 0.62 


















percent of dry 
weight (%) 
Diet      
Males 0.69 ± 0.02 0.43 ± 0.01 0.26 ± 0.01 37.69 ± 0.60 61.03 ± 0.72 
 Females 0.63 ± 0.02 0.41 ± 0.01 0.27 ± 0.01 40.80 ± 0.60 63.32 ± 0.72 
Diet      
+Se 0.68 ± 0.02 0.43 ± 0.01 0.27 ± 0.01 39.64 ± 0.61 62.27 ± 0.73 
-Se 0.65 ± 0.02 0.41 ± 0.01 0.26 ± 0.01 38.85 ± 0.59 62.08 ± 0.71 
 
+I 0.68 ± 0.02 0.43 ± 0.01 0.28 ± 0.01 39.46 ± 0.60 61.82 ± 0.71 














I 0.20 <0.06 0.10 0.61 0.49 
Se 0.38 0.20 0.22 0.36 0.85 
I*Se 0.30 <0.08 0.38 0.67 0.10 
Sex <0.02 <0.02 0.41 <0.002 <0.03 
I*Sex 0.32 0.47 0.41 0.29 0.91 
Se*sex 0.39 <0.08 0.28 0.90 0.36 
I*Se*Sex 0.56 0.58 0.61 0.83 0.75 
Values are least square means ± SEM. Effect is significant at P<0.05.  +Se = Adequate selenium. –Se = Low 















Sex     
Males 188.8 ± 4.2 0.40 ± 0.09 0.292 ± 0.006 4.39 ± 0.14 
 Females 198.4 ± 4.2 0.27 ± 0.09 0.302 ± 0.006 4.16 ± 0.14 
Diet     
+Se 193.7 ± 4.3 0.28 ± 0.09 0.284 ± 0.006 4.51 ± 0.15 
-Se 193.6 ± 4.1 0.39 ± 0.09 0.310 ± 0.006 4.03 ± 0.15 
 
+I 198.1 ± 4.2 0.42 ± 0.09 0.303 ±0.006 4.22 ± 0.15 






P-values P-values P-values 
I 0.15 0.23 0.14 0.65
Se 0.99 0.40 <0.01 <0.05 
I*Se 0.61 0.42 0.23 0.10 
Sex 0.12 0.33 0.21 0.27 
I*Sex 0.57 0.37 0.29 0.19 
Se*sex 0.43 0.35 0.19 0.30 
I*Se*Sex 0.94 0.32 0.74 0.52 
Values are least square means ± SEM.  Effect is significant at P<0.05.  +Se = Adequate selenium. 
-Se = Low selenium, low iodine.  +I = Adequate iodine.  -I = Low iodine.  Ca = Calcium.  Mg = Magnesium.  
Zn = Zinc.  Fe = Iron. 
 
Table XVI















Males 69.76 ± 1.89 78.30 ± 1.60 79.02 ± 2.55 3291.5 ± 141.9 113.2 ± 3.3 127.6 ± 3.4
Females 68.06 ± 1.89 75.14 ± 1.60 81.22 ± 2.55 4023.2 ± 141.9 126.3 ± 3.3 139.7 ± 3.4
Diet
+Se 72.08 ± 1.91 79.41 ± 1.63 81.36 ± 2.62 3461.9 ± 144.1 119.2 ± 3.4 131.6 ± 3.5
-Se 65.74 ± 1.86 74.03 ± 1.58 78.88 ± 2.55 3852.8 ± 139.8 120.3 ± 3.3 135.7 ± 3.4
+I 71.54 ± 1.89 80.06 ± 1.58 85.52 ± 2.56 3768.9 ± 139.8 120.3 ± 3.3 134.9 ± 3.4
-I 66.28 ± 1.89 73.38 ± 1.63 74.73 ± 2.61 3545.8 ± 144.1 119.2 ± 3.4 132.4 ± 3.5
Source of
variation P-values P-values P-values P-values
I <0.07 <0.005 <0.02 0.27 0.82 0.60
Se <0.03 <0.03 0.52 <0.06 0.82 0.40
I*Se <0.07 <0.03 0.83 0.29 0.32 0.42
Sex 0.53 0.17 0.54 <0.0006 <0.008 <0.02
I*Sex 0.45 0.55 <0.05 0.28 0.74 0.99
Se*sex 0.70 0.45 0.48 0.72 0.99 0.78
I*Se*Sex 0.99 0.81 0.42 0.79 0.56 0.56




Figure 16: Interaction effects of iodine and selenium on the yield force and ultimate force 










+I                          -I
Diets
With +I: +Se > -Se (P<0.002)
With -I: +Se vs. -Se (ns)
With +Se: +I > -I (P<0.0007)


















Males                            Females
Diets
In Females: +I > -I  (P<0.002)
In Males: +I vs. -I (ns)
With +I: Male < Female (P<0.07)

















+I                         -I
Diets
With +I: +Se > -Se (P<0.009)
With -I: +Se vs. -Se (ns)
With +Se: +I > -I (P<0.02)












Effects of sex and diet on L3 total force, physiological force, average strain, stiffness, size independent stiffness, and average von















Males 1245 ± 85 3.74 ± 0.25 0.183 ± 0.009 362073 ± 25065 374.4 ± 27.7 56.12 ± 1.97
Females 2016 ± 83 6.05 ± 0.25 0.262 ± 0.008 618366 ± 24591 674.2 ± 27.2 43.79 ± 1.94
Diet
+Se 1567 ± 86 4.70 ± 0.26 0.217 ± 0.009 461823 ± 25428 493.5 ± 28.2 50.23 ± 1.99
-Se 1695 ± 82 5.08 ± 0.25 0.228 ± 0.008 518616 ± 24215 555.2 ± 27.0 49.68 ± 1.91
+I 1555 ± 82 4.67 ± 0.25 0.214 ± 0.008 445903 ± 24215 499.1 ± 27.3 50.23 ± 1.93




P-values P-values P-values P-values P-values P-values
I 0.21 0.21 0.17 0.24 0.23 0.84
Se 0.28 0.28 0.37 0.35 0.15 0.84
I*Se <0.08 <0.08 <0.08 0.34 <0.05 <0.07
Sex <0.0001 <0.0001 <0.0001 <0.09 <0.0003 <0.0005
I*Sex 0.72 0.72 0.87 0.84 0.84 0.66
Se*sex 0.30 0.30 0.80 0.72 0.27 0.48
I*Se*Sex 0.82 0.82 0.93 0.63 0.80 0.41
Values are least square means ± SEM. Effect is significant at P<0.05. +Se = Adequate selenium. –Se = Low selenium. +I = Adequate iodine.












With +I: +Se < -Se (P<0.03)
With -I: +Se vs. -Se (ns)
With +Se: +I < -I (P<0.04)
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In this study we investigated the effects of iodine and/or selenium depletion on 
growth and bone quality of rats.  To ascertain the iodine status of the rats we assessed 
thyroid weight, serum thyroxin, and triiodothyronine.  Selenium status was determined by 
hepatic glutathione peroxidase activity.   
Growth and Bone Density. Weight gain was reduced by iodine depletion in all the 
animals and by selenium depletion in male rats.  Selenium depletion reduced growth, bone 
mineral area, content, and density in males without affecting the values in females.  
Thyroid hormone (T3) concentrations were lower in males than females when selenium was 
depleted.  Cortical thickness of the femur was reduced by selenium depletion in all the 
animals.  Iodine and selenium depletion independently reduced BMA and bone length in 
tibia and femur and selenium depletion decreased vertebral BMA in male rats.  Males had 
longer tibia and femurs than females.  There were no significant differences between males 
and females with respect to bone mineral density as measured by DEXA.  
Organ weights were higher in females than males and iodine depletion decreased 
both liver weight and spleen weight.  Selenium depletion increased liver weight.  There
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were no diet effects on heart weight. 
 Microarchitecture. Female rats had better cancellous bone microarchitecture than 
male rats as evidenced by lower SMI, higher BV/TV, higher trabecular thickness, higher 
trabecular connectivity and lower trabecular separation than males.  In general, the 
microarchtectural parameters of trabecular bone were impaired in iodine adequate rats when 
selenium was also adequate as shown by by lower BV/TV, TbN, TbTh, ConnD, and higher 
TbSp in iodine adequate rats when selenium was also adequate.  However, when selenium 
was deficient the adequacy of iodine improved the trabecular bone quality as evidenced by 
increased trabecular number and connectivity by iodine adequacy in selenium depleted 
animals as compared with iodine and selenium depleted animals.  In addition there was a 
tendency of improved bone volume fraction by the adequacy of iodine in selenium depleted 
rats as compared to both iodine and selenium depleted animals.  The cortical bone volume 
and thickness were higher in males than females when selenium was adequate, but the 
adequacy of iodine increased cortical porosity in males.  This was consistent with a higher 
circulating TRAP in iodine adequate male rats. 
 Biomechanical Properties. The 3-point bending of the femurs showed that selenium 
depletion decreased the breaking force (yield force and ultimate force) of femur in iodine 
adequate rats.  Also when selenium was adequate, the depletion of iodine decreased the 
breaking force.  In females, iodine depletion decreased femur stiffness without affecting the 
bone stiffness of male rats and the modulus of elasticity was higher in females than males.  
Bone strength (yield stress and ultimate stress) as measured by 3-point bending of the 
femur was also higher in female than male rats.  
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Finite element analysis of the trabecular cores of L3 by µCT showed that force to 
entirely crush the bone and average strain were higher in females while von Mises stress 
was higher in males.  Size independent stiffness of L3 trabecular bone was decreased in 
selenium adequate rats when iodine was also adequate.  This may partially be explained by 
growth rate.   
 Biochemical and Oxidative Status. Male rats had higher bone turnover, higher lipid 
peroxidation and lower femur ash weight than females.  This was evidenced by a 
concomitant higher serum ALP and tartrate resistant acid phosphatase.  Urinary excretion 
of P and Mg were also higher in male than female rats.  Serum osteocalcin was decreased 
by selenium depletion, and osteocalcin concentrations were higher in females than males.  
There were no significant effects of iodine, selenium or sex on urinary Ca and urinary 
DPD. 
 Females had higher serum FRAP, lower TBARS, and higher femur ash weights 
than males.  There were no significant sex effects on femur Ca, Mg, and Fe bone mineral 
content as measured by atomic absorption spectrometry.  Selenium depletion increased 
femur Zn, but decreased femur Fe.  Females had a slower growth rate, but a better bone 
quality as ascertained by less bone turnover, less lipid peroxidation, better bone 
microarchitecture, higher bone ash weight, higher bone volume fraction, and higher bone 




For this study we hypothesized:  
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1. Iodine and/or selenium depletion will not significantly reduce growth and bone density 
of growing rats.  We were able to reject the first hypothesis because selenium 
depletion in male rats significantly reduced growth and bone density of growing rats as 
evidenced by reduced weight gain by iodine depletion in all rats and by selenium 
depletion in males.  Decreased bone mineral area, content and density as well as 
decreased bone length and cortical thickness were also observed in iodine and/or 
selenium depleted animals. 
2. Iodine and/or selenium depletion will not negatively affect biochemical markers of bone 
metabolism and oxidative status of growing rats.  We were able to reject the second 
hypothesis because selenium depletion significantly decreased biomarkers of bone 
formation and impaired antioxidant status as shown by decreased serum osteocalcin 
and serum FRAP by selenium depletion.  An independent increase of liver TBARS by 
iodine and selenium depletion was also observed.  However, the other biomarkers of 
bone metabolism were not affected by either selenium or iodine depletion.   
3. Iodine and/or selenium depletion will not significantly deteriorate the microarchitecture 
of growing rat bone.  We were not able to reject the third hypothesis because the 
combined adequacy of iodine and selenium caused a deterioration of tibial and L3
trabecular bone microarchitecture.  However, when selenium was deficient, the 
adequacy of iodine improved the microarchitecture of the bone as compared to double 
depletion of iodine and selenium.  This was shown by increased tibial trabecular 
number and an increase in both tibial and L3 trabecular connectivity by iodine adequacy 
in selenium deficient rats.  This indicates that combined deficiency of both iodine and 
selenium may be detrimental to bone. 
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4. Iodine and or selenium depletion will not impair biomechanical properties of the bone of 
growing rats.  We were able to reject the fourth hypothesis because iodine and selenium 
depletion decreased femur bending force in all the animals as evidenced by decreased 
yield force and ultimate force by iodine and selenium depletion in selenium and iodine 
adequate rats respectively.  In addition, iodine depletion decreased femur stiffness in 
female rats.  However the combined adequacy of iodine and selenium reduced the 
compressive stiffness of L3 trabecular cores.   
5. Male and female rat bones will not be differently affected by iodine and/selenium 
depletion.  We were able to reject the fifth hypothesis because selenium depletion had 
more effects on the bone of males, as evidenced by decreased weight gain, BMA, BMC 
and BMD by selenium depletion in males without affecting female rats.  In general, 
iodine depletion affected both males and females, but there was a slight trend toward 
more effects of iodine depletion on females.  This trend was supported by a significant 
decrease of femur stiffness in female by iodine depletion without affecting the bone 
thickness of male rats.  This sex difference in response of bone to iodine and selenium 
depletion was accompanied by a slower growth rate, smaller bone size, lower bone 
turnover, better bone microarchitecture, less lipid peroxidation, and higher bone 
strength in female than male rats. 
 
Suggestions for Further Studies 
 
• Because lipid peroxidation was increased by both iodine and selenium depletion, 
and antioxidant status was impaired by selenium depletion, it would be interesting 
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to assess inflammatory markers such as IL1, IL-6, and TNF-α, and C-reactive 
protein to see whether increased lipid peroxidation and decreased antioxidant staus  
in selenium-deficient rats are accompanied by increased levels of these cytokines. 
Lipid peroxidation may lead to the generation of reactive oxygen species (ROS).  
ROS in high concentration damage bone cells and increase the production of 
inflammatory cytokines (79).  These cytokines are necessary for osteoclast activity 
and increase their own activities by inducing the production of ROS (79)   
• Because growth has been affected by both iodine and selenium, assessment of IGF-
1, IGF-binding proteins, and growth hormone and their association with bone 
quality should be determined. 
• We assumed that iodine and/or selenium depletion would cause osteoarthritis-like 
symptoms and that osteoarthtis would lead to impaired bone quality.  But we did 
not directly assess any indices of osteoarthritis.  Histomorphometric analysis of rat 
joint structure is needed as well as the assessment of biomarkers of osteoarthritis 
and rheumatoid arthritis.  Diagnosis of osteoarthritis currently relies on clinical 
history and radiography in humans.  However potential biomarkers of osteoarthritis 
have been proposed by Haq and colleagues (54).  These markers include indices of 
cartilage destruction such as cartilage oligomeric matrix protein (COMP) and 
markers of synovial inflammation (C-reactive protein, hyaluronan, YKL-40, and 
metalloproteinases).  Some of these potential markers for osteoarthritis will be 
assessed.  Potential biomarkers of rheumathoid arthritis such as IL-1β, IL-6 and  
IL-8 (167) and rheumathoid factor IgM could also be determined in iodine and/or 
selenium-depleted growing rats. 
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Composition of the mineral mix  
________________________________________________________________________                                                                                                                                             
Mineral                                                                                                       g/kg mix 
________________________________________________________________________ 
Essential mineral elements                     
 Calcium carbonate, anhydrous, 40.04% Ca                                             357.00 
 Potassium phosphate, monobasic, 22.76% P; 28.73% K                         250.00 
 Sodium chloride, 39.34% Na; 60.66% Cl                                                  74.00 
 Potassium sulfate, 44.87% K; 18.39% S                                                    46.60 
 Potassium citrate, tri-potassium, monohydrate, 36.16% K                        28.00 
 Magnesium oxide, 60.32% Mg                                                                  24.00 
 Ferric citrate, 16.5% Fe                                                                                6.06 
 Zinc carbonate, 52.14% Zn                                                                          1.65 
 Manganous carbonate, 47.79% Mn                                                              0.63 
 Cupric carbonate, 57.47% Cu                                                                       0.30 
 ∗Potassium iodate, 59.3% I                                                                          0.01 
 ∗∗Sodium selenate, anhydrous, 41.79% Se                                            0.01025 
 Ammonium paramolybdate, 4 hydrate, 54.34% Mo                              0.00795 
Potentially beneficial mineral elements 
 Sodium meta-silicate, 9 hydrate, 9.88% Si                                                   1.45 
 Chromium potassium sulfate, 12 hydrate, 10.42% Cr                                0.275 
 Boric acid, 17.5% B                                                                                  0.0815 
 Sodium fluoride, 45.24% F                                                                       0.0635 
 Nickel carbonate, 45% Ni                                                                         0.0318 
 Lithium chloride 16.38% Li                                                                      0.0174 
 Ammonium vanadate, 43.55% V                                                              0.0066 
 Powdered sucrose                                                                                    209.806 
_________________________________________________________________ 
∗The mineral mix for the diets depleted in I was prepared without adding potassium iodate.   
 ∗∗The mineral mix for selenium depleted diets was prepared without adding sodium selenate.   
The mineral mix for the diet depleted in both iodine and selenium was prepared without adding  





Composition of the Vitamin Mix 
________________________________________________________________________ 
Vitamin                                                                                                g/kg mix 
________________________________________________________________________ 
Nicotinic acid                                                                                        3.000 
Ca pentothenate                                                                                     1.600 
Pyridoxine-HCl                                                                                     0.700 
Thiamin-HCl                                                                                         0.600 
Riboflavin                                                                                             0.600 
Folic acid                                                                                              0.200 
D-Biotin                                                                                                0.020 
Vitamin B12 (cyanocobalamin in 0.1% manitol)                                 2.500 
Vitamin E (all-rac-α-tocopheryl acetate) (500 IU/g)                           15.00 
Vitamin A (all trans Retinyl palmitate)(500,000 IU/g)                       0.800 
Vitamin D3 (cholecalciferol) (400,000 IU/g)                                       0.250 
Vitamin K (phyloquinone)                                                                    0.075 




Effects of the diets on weight gain, thyroid weight, serum thyroid hormones, and liver glutathione peroxidase activity












+Se+I Male (9) 223.86 ± 6.63 0.0060 ± 0.0004 3.642 ± 0.154 62.667 ± 3.468 14.774 ± 1.034
Female (9) 149.18 ± 4.21 0.0071 ± 0.0012 3.328 ± 0.092 66.244 ± 4.193 12.966 ± 1.314
+Se-I Male (8 197.06 ± 6.53 0.0562 ± 0.0060 0.393 ± 0.047 51.871 ± 1.947 14.888 ± 1.874
Female (8) 126.12 ± 2.62 0.0730 ± 0.0068 0.720 ± 0.148 63.264 ± 2.185 14.178 ± 2.188
-Se+I Male (9) 178.33 ± 3.23 0.0061 ± 0.0005 4.375 ± 0.486 52.529 ± 3.082 1.836 ± 0.443
Female (9) 137.73 ± 2.40 0.0082 ± 0.0009 4.345 ± 0.298 66.553 ± 3.103 1.572 ± 0.246
-Se-I Male (9) 163.60 ± 8.72 0.0644 ± 0.0089 0.401 ± 0.098 48.818 ± 4.759 1.374 ± 0.212
Female (9) 122.84 ± 6.05 0.0681 ± 0.0104 0.963 ± 0.518 72.413 ± 6.410 1.005 ± 0.295
Source of
Variation P-value P-values P-values P-values P-values
I <0.008 <0.0001 <0.0001 0.45 0.93
Se <0.002 0.80 <0.08 0.78 <0.0001
I*Se 0.43 0.91 0.18 0.30 0.49
Sex <0.0001 0.15 0.53 <0.0001 0.33
I*Sex 0.87 0.30 0.18 0.11 0.76
Se*sex <0.004 0.47 0.54 <0.05 0.56
I*Se*Sex 0.99 0.40 0.96 0.85 0.71
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine.




Effects to the diets on tibia and femur bone mineral area, bone mineral content, and bone mineral density by dual energy x-ray
absorptiometry












+Se+I Male (9) 1.404 ± 0.037 0.238 ± 0.009 0.170 ± 0.003 1.681 ± 0.041 0.385 ± 0.015 0.228 ± 0.003
Female (9) 1.245 ± 0.027 0.207 ± 0.006 0.166 ± 0.003 1.503 ± 0.037 0.341 ± 0.012 0.226 ±0.003
+Se-I Male (8 1.317 ± 0.025 0.219 ± 0.007 0.166 ± 0.002 1.576 ± 0.073 0.349 ± 0.014 0.222 ± 0.004
Female (8) 1.094 ± 0.023 0.177 ± 0.006 0.161 ± 0.002 1.344 ± 0.031 0.296 ± 0.008 0.220 ± 0.003
-Se+I Male (9) 1.295 ± 0.022 0.210 ± 0.004 0.162 ± 0.001 1.542 ± 0.036 0.341 ± 0.008 0.221 ± 0.001
Female (9) 1.148 ± 0.014 0.192 ± 0.004 0.167 ± 0.002 1.472 ± 0.034 0.332 ± 0.007 0.225 ± 0.003
-Se-I Male (9) 1.211 ± 0.037 0.196 ± 0.009 0.163 ± 0.003 1.510 ± 0.043 0.327 ± 0.013 0.216 ± 0.004
Female (9) 1.104 ± 0.048 0.181 ± 0.011 0.163 ± 0.004 1.343 ± 0.036 0.299 ± 0.013 0.222 ± 0.005
Source of
Variation P-values P-values P-values P-values P-values P-values
I <0.02 <0.06 0.42 <0.04 <0.06 0.19
Se <0.03 <0.08 0.41 0.15 0.18 0.45
I*Se 0.37 0.44 0.77 0.57 0.53 0.68
Sex <0.0001 <0.0001 0.65 <0.0001 <0.0006 0.57
I*Sex 0.74 0.67 0.65 0.12 0.30 0.82
Se*sex 0.12 <0.03 <0.07 <0.08 <0.05 0.24
I*Se*Sex 0.20 0.39 0.94 0.85 0.97 0.84
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium low iodine.




Effects of the diets on vertebral bone mineral area, bone mineralcontent, and bone mineral density by dual energy x-ray
absorptiometry




+Se+I Male (9) 1.531 ± 0.034 0.362 ± 0.012 0.236 ± 0.006
Female (9) 1.319 ± 0.025 0.301 ± 0.009 0.228 ± 0.004
+Se-I Male (8 1.423 ± 0.036 0.331 ± 0.012 0.232 ± 0.006
Female (8) 1.242 ± 0.026 0.272 ± 0.009 0.219 ± 0.004
-Se+I Male (9) 1.413 ± 0.024 0.310 ± 0.007 0.220 ± 0.005
Female (9) 1.302 ± 0.016 0.297 ± 0.007 0.228 ± 0.004
-Se-I Male (9) 1.367 ± 0.046 0.292 ± 0.013 0.213 ± 0.004
Female (9) 1.271 ± 0.038 0.276 ± 0.014 0.216 ± 0.006
Source of
Variation P-values P-values P-values
I 0.12 <0.08 0.14
Se 0.28 <0.08 <0.07
I*Se 0.46 0.67 0.76
Sex <0.0001 <0.0001 0.38
I*Sex 0.67 0.90 0.47
Se*sex <0.02 <0.002 <0.03
I*Se*Sex 0.94 0.99 0.90
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium,low iodine.
-Se+I = Low selenium, adequate iodine. -Se-I = Low selenium, low iodine. Vertebral = L3-5 = Lumbar 3, Lumbar 4, and Lumbar 5 together. BMA = Bone
mineral area. BMC = Bone mineral content. BMD = Bone mineral density.
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APPENDIX G
Effect of the diets on tibia trabecular total volume, bone volume, bone volume fraction, bone surface, bone surface over bone
volume, and degree of anisotropy by micro computed tomography
Diet Gender (n) Tibia TV (mm3) Tibia BV
(mm3)






+Se+I Male (9) 27.481 ± 0.843 2.491 ± 0.115 0.091 ± 0.005 114.857 ± 5.204 51.518 ± 1.099 2.508 ± 0.033
Female (9) 20.807 ± 1.008 2.546 ± 0.211 0.124 ± 0.010 107.353 ± 7.264 46.801 ± 1.268 2.318 ± 0.032
+Se-I Male (8 23.688 ± 0.764 2.716 ± 0.233 0.115 ± 0.010 121.063 ± 9.519 50.028 ± 0.979 2.267 ± 0.062
Female (8) 17.221 ± 0.460 2.538 ±0.161 0.147 ± 0.009 105.259 ± 6.454 45.036 ± 0.576 2.006 ± 0.146
-Se+I Male (9) 23.653 ± 0.379 2.794 ± 0.137 0.118 ± 0.005 129.156 ± 5.328 51.513 ± 1.000 2.353 ± 0.022
Female (9) 19.481 ± 0.304 3.138 ± 0.098 0.161 ± 0.005 129.642 ± 3.686 44.760 ± 0.079 2.228 ± 0.029
-Se-I Male (9) 1.956 ± 0.232 0.087 ± 0.007 90.792 ± 9.622 53.175 ± 1.191 2.206 ± 0.038
Female (9) 16.288 ± 0.561 2.296 ± 0.247 0.138 ± 0.012 95.206 ± 9.416 45.795 ± 1.059 2.023 ± 0.039
Source of
Variation P-values P-values P-values P-values P-values P-values
I <0.002 0.10 0.79 <0.05 0.87 <0.0001
Se <0.02 0.97 0.34 0.98 0.82 <0.09
I*Se 0.35 <0.06 <0.03 <0.05 0.25 0.23
Sex <0.0001 0.19 <0.0001 0.39 <0.0001 <0.0001
I*Sex 0.50 0.67 0.63 0.88 0.78 0.44
Se*sex 0.15 0.11 0.23 0.16 0.23 0.39
I*Se*Sex 0.46 0.73 0.83 0.60 0.99 0.93
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine. -
Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. SMI = Structural model index. TbTh = Trabecular thickness. ConnD =
Connectivity density. BV/TV = Bone volume over total volume. BV = Bone volume. BS = Bone surface. DA = Degree of anisotropy.
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APPENDIX H
Effect of the diets on tibia trabecular structural model index, number, thickness, and connectivity density by microcomputed
tomography








+Se+I Male (9) 2.662 ± 0.042 2.662 ± 0.042 0.053 ± 0.001 35.359 ± 3.608
Female (9) 2.365 ± 0.081 3.262 ± 0.149 0.056 ± 0.001 63.809 ± 7.438
+Se-I Male (8 2.540 ± 0.064 3.552 ± 0.237 0.054 ± 0.001 59.507 ± 8.135
Female (8) 2.243 ± 0.054 3.927 ± 0.188 0.058 ± 0.001 80.277 ± 8.743
-Se+I Male (9) 2.468 ± 0.040 3.859 ± 0.141 0.052 ± 0.001 63.830 ± 4.609
Female (9) 2.139 ± 0.043 4.223 ± 0.151 0.058 ± 0.001 93.310 ± 3.034
-Se-I Male (9) 2.666 ± 0.066 3.013 ± 0.180 0.051 ± 0.001 38.545 ± 4.826
Female (9) 2.314 ± 0.081 3.735 ± 0.242 0.058 ± 0.001 75.988 ± 9.594
Source of
Variation P-values P-values P-values P-values
I 0.59 0.78 0.61 0.85
Se 0.34 0.11 0.72 0.17
I*Se <0.08 <0.004 0.56 <0.01
Sex <0.0001 <0.001 <0.0001 <0.0001
I*Sex 0.80 0.30 0.35 0.91
Se*sex 0.70 0.37 0.16 0.39
I*Se*Sex 0.99 0.70 0.71 0.46
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine. –Se+I =
Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. SMI = Structural model index. TbTh = Trabecular thickness. ConnD = Connectivity density.
BV/TV = Bone volume over total volume. BV = Bone volume
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APPENDIX I
Effect of the diets on tibia cortical total volume, bone volume, bone volume fraction, thickness, porosity, and surface by
microcomputed tomography















+Se+I Male (9) 2.700 ± 0.091 2.603 ± 0.091 0.964 ± 0.003 0.487 ± 0.013 3.630 ± 0.319 3.507 ± 0.128
Female (9) 2.334 ± 0.055 2.265 ± 0.056 0.971 ± 0.001 0.477 ± 0.008 2.943 ± 0.138 3.062 ± 0.076
+Se-I Male (8 2.438 ± 0.096 2.374 ± 0.090 0.974 ± 0.002 0.512 ± 0.012 2.537 ± 0.252 3.112 ± 0.125
Female (8) 2.209 ± 0.099 2.145 ± 0.097 0.971 ± 0.001 0.478 ± 0.013 2.961 ± 0.155 4.342 ± 1.546
-Se+I Male (9) 2.378 ± 0.044 2.303 ± 0.042 0.969 ± 0.002 0.476 ± 0.005 3.137 ± 0.172 3.116 ± 0.057
Female (9) 2.304 ± 0.031 2.237 ± 0.032 0.971 ± 0.002 0.473 ± 0.008 2.928 ± 0.208 3.026 ± 0.043
Male (9) 2.430 ± 0.077 2.364 ± 0.077 0.973 ± 0.002 0.490 ± 0.012 2.748 ± 0.144 3.197 ± 0.104
Female (9) 2.272 ± 0.068 2.207 ± 0.068 0.971 ± 0.001 0.512 ± 0.019 2.767 ± 0.181 2.970 ± 0.093
Source of
Variation P-values P-values P-value P-values P-values P-values
I 0.15 0.19 <0.04 <0.06 <0.04 0.53
Se 0.40 0.43 0.44 0.73 0.44 0.23
I*Se 0.11 0.12 0.46 0.24 0.46 0.55
Sex <0.002 <0.002 0.43 0.31 0.43 0.74
I*Sex 0.99 0.87 <0.03 0.82 <0.03 0.27
Se*sex <0.06 <0.07 0.87 <0.04 0.87 0.44
I*Se*Sex 0.50 0.56 0.13 0.08 0.13 0.21
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium,
low iodine. –Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. TV = Total volume. BV = Bone volume.
BV/TV = Bone relative volume. Cortical porosity = ((1- (BV/TV))*100. Cortical bone surface = TRI BV/(44*0.0165).
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APPENDIX J
Effects of the diets on L3 trabecular total volume, bone volume, bone volume fraction, connectivity density, and degree of anisotropy by
microcomputed tomography






+Se+I Male (9) 12.638 ± 0.530 2.360 ± 0.186 0.185 ± 0.010 63.000 ± 3.334 1.840 ± 0.029
Female (9) 11.281 ± 0.455 2.501 ± 0.123 0.221 ± 0.004 78.541 ± 2.567 1.909 ± 0.027
+Se-I Male (8) 11.853 ± 0.887 2.509 ± 0.239 0.210 ± 0.010 72.394 ± 3.657 1.807 ± 0.030
Female (8) 8.937 ± 0.535 2.185 ± 0.165 0.243 ± 0.007 77.437 ± 2.358 1.931 ± 0.024
-Se+I Male (9) 11.479 ± 0.516 2.343 ± 0.143 0.204 ± 0.007 75.400 ± 2.211 1.783 ± 0.023
Female (9) 9.664 ± 0.228 2.593 ± 0.111 0.268 ± 0.008 86.208 ± 2.292 1.945 ± 0.022
-Se-I Male (9) 10.029 ±0.557 1.886 ± 0.156 0.186 ± 0.007 65.071 ± 3.749 1.807 ± 0.030
Female (9) 9.664 ± 0.311 2.352 ± 0.150 0.243 ± 0.014 75.044 ± 2.207 1.868 ± 0.019
Source of
variation P-values P-values P-values P-values P-values
I <0.07 0.30 0.77 0.18 0.49
Se 0.09 0.52 0.27 0.30 0.39
I*Se 0.46 0.43 <0.03 <0.005 0.67
Sex <0.0001 0.37 <0.0002 <0.0005 <0.0002
I*Sex 0.82 0.54 0.77 0.22 0.71
Se*sex 0.10 <0.07 0.08 0.99 0.70
I*Se*Sex <0.03 0.12 0.97 0.31 0.07
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium,
low iodine. –Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. TV= Total volume. BV = Bone volume.
BV/TV = Bone volume over total volume. ConnD = Connectivity density.
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APPENDIX K
Effect of the diets on L3 trabecular structural model index, number, thickness, separation, and bone surface over bone volume by
microcomputed tomography










+Se+I Male (9) 1.236 ± 0.089 3.158 ± 0.071 0.070 ± 0.001 0.316 ± 0.008 78.590 ± 5.169 34.499 ± 0.816
Female (9) 0.867 ± 0.048 3.567 ± 0.048 0.069 ± 0.001 0.274 ± 0.004 82.503 ± 3.830 33.518 ± 0.272
+Se-I Male (7) 1.023 ± 0.085 3.435 ± 0.083 0.070 ± 0.002 0.286 ± 0.008 81.722 ± 6.659 33.622 ± 0.919
Female (8) 0.368 ± 0.201 3.740 ± 0.062 0.070 ± 0.001 0.261 ± 0.004 68.656 ± 4.332 32.114 ± 0.756
-Se+I Male (9) 1.028 ± 0.070 3.322 ± 0.048 0.068 ± 0.001 0.298 ± 0.005 78.437 ± 4.108 34.362 ± 0.643
Female (9) 0.161 ± 0.140 3.842 ± 0.046 0.073 ± 0.001 0.253 ± 0.004 79.009 ± 2.470 30.787 ± 0.616
-Se-I Male (9) 1.189 ± 0.039 3.271 ± 0.065 0.067 ± 0.001 0.303 ± 0.007 64.917 ± 4.945 35.494 ± 0.509
Female (9) 0.556 ± 0.172 3.657 ± 0.073 0.073 ± 0.002 0.268 ± 0.006 72.587 ± 2.959 31.645 ± 1.018
Source of
variation P-values P-values P-values P-values P-values P-values
I 0.68 0.27 0.79 0.16 0.13 0.78
Se 0.18 0.33 0.92 0.37 0.32 0.70
I*Se <0.02 <0.006 0.54 <0.0006 0.57 0.18
Sex <0.0001 <0.0001 <0.04 <0.0001 0.83 <0.0006
I*Sex 0.85 0.19 0.82 0.11 0.40 0.74
Se*sex 0.18 0.29 <0.02 0.47 0.17 <0.03
I*Se*Sex 0.14 0.87 0.69 0.74 0.07 0.93
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine.
–Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. SMI= Structural model index. TbN = Trabecular number. TbTh = Trabecular
thickness. TbSp = Trabecular separation. BS = Bone surface. BS/BV = Bone surface over bone volume.
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APPENDIX L
Effects of the diets on serum alkaline phosphatase, osteocalcin, tartrate resistant acid phophatase, ferric reducing ability of plasma, and liver
thiobarbituric acid reactive substances












+Se+I Male (9) 112.8 ± 8.4 33.1 ±1.7 7.09± 0.40 585.5 ± 39.5 0.269 ± 0.005
Female (9) 86.9 ± 9.1 34.1 ± 2.0 6.16 ± 0.36 631.9 ± 87.8 0.261 ± 0.004
+Se-I Male (8) 87.0 ± 8.3 47.7± 6.9 6.20 ± 0.90 644.2 ± 79.1 0.289 ± 0.005
Female (8) 56.9 ± 6.2 56.0 ± 6.7 6.26 ± 0.42 1090.1 ± 117.4 0.251 ± 0.006
-Se+I Male (9) 92.1 ± 5.3 25.0 ± 2.3 7.09 ± 0.37 502. 6 ± 46.5 0.297 ± 0.003
Female (9) 64.4 ± 6.4 31.1 ± 1.7 5.33 ± 0.54 488.0 ± 63.8 0.269 ± 0.006
-Se-I Male (9) 71. 5 ± 17.5 24.0 ± 2.0 5.97 ± 0.79 382.2 ± 24.1 0.311 ± 0.004
Female (9) 78.1 ± 12.2 30.1 ± 3.5 5.81 ± 0.60 691.8 ± 107.3 0.286 ± 0.004
Source of
variation P-values P-values P-values P-values P-values
I 0.30 0.21 0.69 0.13 <0.03
Se 0.49 <0.04 0.67 <0.03 <0.0001
I*Se 0.31 0.17 0.82 0.18 0.17
Sex <0.03 <0.02 <0.04 <0.02 <0.0001
I*Sex 0.27 0.21 <0.06 <0.03 0.20
Se*sex 0.32 0.96 0.46 0.54 0.62
I*Se*Sex 0.21 0.23 0.58 0.67 <0.06
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine.
-Se+I = Low selenium, adequate iodine. -Se-I = Low selenium, low iodine. ALP = Alkaline phosphatase. TRAP = Tartrate resistant acid phosphatase.
FRAP = Ferric reducing ability of plasma. TBARS = Thiobarbituric acid reactive substances.
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APPENDIX M
Effects of the diets on urinary, calcium, phosphorus, magnesium, creatinine, and deoxypyridinoline excretion











+Se+I Male (9) 0.74 ± 0.12 9.57 ± 1.02 3.21 ± 0.48 3.36 ± 0.73 251.245 ± 34.20
Female (9) 2.93 ± 2.14 8.71 ± 2.57 1.97 ± 0.21 2.62 ± 0.58 179 67 ± 23.71
+Se-I Male (8) 0.81 ± 0.21 6.67 ± 0.88 2.76 ± 0.78 3.07 ± 0.57 154.67 ± 18.68
Female (8) 0.71 ± 0.18 4.79 ± 0.88 1.87 ± 0.34 1.95 ± 0.25 205.48 ± 19.35
-Se+I Male (9) 0.88 ± 0.09 8.97 ± 0.35 2.97 ± 0.29 2.30 ± 0.29 154.72 ± 10.31
Female (9) 1.00 ± 0.21 6.37 ± 0.50 2.27 ± 0.34 2.06 ± 0.31 340.04 ± 91.40
-Se-I Male (9) 0.98 ± 0.24 5.02 ± 0.54 1.57 ± 0.18 2.50 ± 0.54 111.50 ± 8.99
Female (9) 0.86 ± 0.13 4.72 ± 0.58 1.53 ± 0.21 1.91 ± 0.31 261.35 ± 77.92
Source of
variation P-values P-values P-values P-values P-values P-values
I 0.40 0.09 0.09 0.73 0.41
Se 0.46 0.11 0.28 0.25 0.74
I*Se 0.40 <0.07 0.27 0.69 0.82
Sex 0.51 <0.04 <0.007 <0.03 0.18
I*Sex 0.29 0.78 0.35 0.51 0.70
Se*sex 0.30 0.43 0.18 0.41 0.13
I*Se*Sex 0.37 0.92 0.69 0.90 0.49
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine.
–Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. Ca = Calcium. P = Phosphorus. Mg = Magnesium. DPD = Deoxypyridinoline.
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APPENDIX N
Effects of the diets tibia length, body lean mass, body fat mass, liver weight, spleen weight, and heart weight













+Se+I Male (9) 39.28 ± 0.48 92.16 ± 0.33 7.85 ± 0.33 3.07 ± 0.12 0.252 ± 0.006 0.400 ± 0.022
Female (9) 37.12 ± 0.30 92.35 ± 0.41 7.65 ± 0.41 3.44 ± 0.08 0.303 ± 0.010 0.455 ± 0.016
+Se-I Male (8) 37.06 ± 0.54 91.60 ± 0.52 8.40 ± 0.52 3.07 ± 0.05 0.227 ± 0.006 0.392 ± 0.007
Female (8) 35.14 ± 0.21 93.16 ± 0.50 6.84 ± 0.50 3.34 ± 0.05 0.274 ± 0.006 0.457 ± 0.014
-Se+I Male (9) 37.71 ± 0.12 95.34 ± 0.36 8.66 ± 0.36 3.51 ± 0.04 0.240 ± 0.008 0.389 ± 0.009
Female (9) 35.80 ± 0.29 92.24 ± 0.37 7.76 ± 0.37 3.72 ± 0.06 0.284 ± 0.004 0.462 ± 0.012
-Se-I Male (9) 35.99 ± 0.36 92.59 ± 0.36 7.41 ± 0.36 3.13 ± 0.09 0.221 ± 0.007 0.396 ± 0.017
Female (9) 34.50 ± 0.49 92.57 ± 0.67 7.43 ± 0.67 3.42 ± 0.20 0.270 ± 0.010 0.497 ± 0.039
Source of
Variation P-values P-values P-values P-values P-values P-values
I <0.0006 0.27 0.27 <0.02 <0.004 0.64
Se <0.007 0.80 0.80 <0.005 0.10 0.66
I*Se 0.3844 0.36 0.36 <0.06 0.41 0.52
Sex <0.0001 <0.04 <0.04 <0.0004 <0.0001 <0.0006
I*Sex 0.55 0.71 0.71 0.97 0.99 0.58
Se*sex 0.49 0.47 0.47 0.63 0.84 0.57
I*Se*Sex 0.83 <0.07 <0.07 0.54 0.71 0.83
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine.
–Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. BW = Body weight.
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APPENDIX O
Effects the diets on femur length (by caliper) and biomechanical properties by 3-point bending








+Se+I Male (9) 34.27± 0.38 0.73 ± 0.06 77.63 ± 4.08 87.35 ± 4.21 84.37 ± 6.95
Female (9) 32.70 ± 0.27 0.72 ± 0.05 76.96 ± 2.22 83.28 ± 2.03 88.35 ± 3.15
+Se-I Male (8) 32.39 ± 0.41 0.68 ± 0.05 68.85 ± 3.96 76.37 ± 3.75 78.64 ± 5.57
Female (8) 30.31 ± 0.30 0.71 ± 0.05 64.46 ± 2.89 70.65 ± 2.89 74.02 ± 5.17
-Se+I Male (9) 32.83 ± 0.20 0.65 ± 0.04 65.08 ± 4.64 74.56 ± 2.83 77.23 ± 4.06
Female (9) 31.25 ± 0.10 0.69 ± 0.02 66.57 ± 2.89 75.05 ± 2.25 92.16 ± 3.26
-Se-I Male (9) 31.86 ± 0.30 0.58 ± 0.03 67.12 ± 3.86 74.91 ± 3.94 75.74 ± 3.93
Female (9) 30.26 ±0.29 0.58 ± 0.04 64.18 ± 2.80 71.60 ± 3.03 70.36 ± 6.84
Source of
Variation P-value P-value P-value P-value P-value
I <0.002 0.11 <0.07 <0.005 <0.02
Se <0.03 <0.04 <0.03 <0.03 0.52
I*Se 0.12 0.41 <0.07 <0.03 0.83
Sex <0.0001 0.69 0.53 0.17 0.54
I*Sex 0.43 0.97 0.45 0.55 <0.05
Se*sex 0.42 0.92 0.70 0.45 0.48
I*Se*Sex 0.43 0.50 0.99 0.81 0.42
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine. –Se+I =
Low selenium, adequate iodine. –Se-I = Low selenium, low iodine.
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APPENDIX P
Effects the diets on femur SMA, modulus of elasticity, yield stress, and ultimate stress by 3-points bending






+Se+I Male (9) 8.12 ± 0.70 3053.67 ± 245.75 113.37 ± 4.76 128.04 ± 6.01
Female (9) 6.63 ± 0.30 3880.00 ± 164.38 130.80 ± 4.93 141.61 ± 4.93
+Se-I Male (8) 7.09 ±0.45 3209.33 ± 162.49 111.93 ± 4.17 124.38 ± 3.84
Female (8) 5.77 ± 0.26 3704.44 ± 244.49 120.72 ± 5.01 132.36 ± 5.43
-Se+I Male (9) 6.45 ± 0.36 3532.85 ± 267.89 112.60 ± 8.85 129.79 ± 6.98
Female (9) 5.79 ± 0.16 4608.94 ± 201.87 124.39 ± 5.60 140.19 ± 4.46
-Se-I Male (9) 6.60 ± 0.38 3369.93 ± 208.83 115.01 ± 7.27 128.32 ± 7.54




P-value P-value P-value P-value
I 0.22 0.27 0.82 0.61
Se <0.05 <0.060. 0.82 0.40
I*Se 0.28 0.29 0.32 0.42
Sex <0.0001 <0.0006 <0.008 <0.02
I*Sex 0.72 0.28 0.74 0.99
Se*sex 0.33 0.72 0.99 0.79
I*Se*Sex 0.60 0.79 0.56 0.56
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate selenium, low iodine.
–Se+I = Low selenium, adequate iodine. –Se-I = Low selenium, low iodine. SMA = Second moment of area.
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APPENDIX Q
Effects of the diets on L3 average strain, total force, and Stiffness, Size Independent stiffness, and average von
Mises stress using finite element analysis (FE) by MicroCT





+Se+I Male (9) 0.158 ± 0.020 1026.07 ± 158.28 283403.22 ± 42052.42 295.76 ± 50.55 60.228 ± 4.552
Female (9) 0.237 ± 0.018 1742.48 ± 155.65 491572.44 ± 43028.72 547.60 ± 46.84 46.307 ± 2.096
+Se-I Male (8) 0.200 ± 0.014 1459.69 ± 180.55 400147.57 ± 47642.24 437.36 ± 46.36 50.747 ± 5.435
Female (8) 0.273 ± 0.017 2037.75 ± 151.15 672170.13 ± 37345.80 693.14 ± 48.88 43.822 ± 1.963
-Se+I Male (9) 0.189 ± 0.010 1272.13 ± 98.01 361305.33 ± 25263.35 394.63 ± 32.54 53.806 ± 2.711
Female (9) 0.272 ± 0.012 2180.64 ± 133.97 647332.56 ± 38578.16 759.28 ± 44.02 40.496 ± 1.788
-Se-I Male (9) 0.185 ± 0.014 1222.91 ± 118.66 403434.56 ± 35430.45 369.92 ± 37.51 59.856 ± 5.065
Female (9) 0.266 ± 0.023 2102.26 ± 275.33 662390.33 ± 92053.34 696.76 ± 88.71 44.541 ± 4.377
Source of
Variation P-values P-values P-values P-values P-value
I 0.17 0.21 0.24 0.23 0.84
Se 0.37 0.28 0.35 0.15 0.84
I*Se <0.08 <0.08 0.34 <0.05 <0.07
Sex <0.0001 <0.0001 0.09 <0.0003 <0.0005
I*Sex 0.86 0.72 0.84 0.84 0.66
Se*sex 0.80 0.30 0.72 0.27 0.48
I*Se*Sex 0.93 0.82 0.63 0.80 0.41
Values are least square means ± SEM. Effect is significant at P<0.05. +Se+I = Adequate selenium, adequate iodine. +Se-I = Adequate
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